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1. RIASSUNTO 
 
L’Anemia Aplastica è una rara patologia ematologica, prototipo delle sindromi 
da insufficienza midollare, caratterizzata da un progressiva riduzione del patrimonio 
di cellule staminali midollari che esita nel classico quadro istologico di midollo “vuoto” 
o “grasso”. Il quadro clinico è dominato dai sintomi tipici dell’insufficienza midollare, 
come astenia, petecchie e/o febbre, e può rapidamente deteriorarsi per l’insorgere di 
complicanze quali emorragie e/o infezioni, potenzialmente fatali. L’Anemia Aplastica 
colpisce generalmente 1-2/106 individui l’anno, con un’incidenza stimata nei paesi 
orientali di circa 2-3 volte superiore a quelli osservati in Occidente. 
Sebbene l’etiologia rimanga sconosciuta nella maggior parte dei casi, in un 
quinto circa dei pazienti è riconoscibile una causa scatenante quale: esposizione a 
tossine (ad es. Benzene) e/o farmaci (ad es. FANS, sali d’oro, etc.) e/o agenti virali 
(ad es. Parvovirus B19, EBV, etc.). Raramente la diagnosi segue un episodio di 
epatite sieronegativa ed auto-limitantesi. A prescindere dal fattore scatenante, la 
patogenesi dell’Anemia Aplastica è immuno-mediata, ed è determinata dall’azione 
citotossica dei linfociti T che attaccano le cellule staminali ematopoietiche, 
determinandone la morte per apoptosi. Questo meccanismo autoimmune determina 
un difetto quantitativo e qualitativo delle cellule staminali, tipico della malattia. 
Recentemente tuttavia, la scoperta che le cellule staminali dei pazienti aplastici 
possono presentare telomeri corti, mutazioni dei geni del comlpesso telomerasico, e 
mutazioni in alcuni geni fondamentali nella regolazione epigentica del DNA, hanno 
suggerito che il danno funzionale del midollo osseo non derivi soltanto da 
meccanismi estrinseci immuno-mediati, ma anche intrinseci, derivanti da un primitivo 
deficit genico del comparto staminale. 
La patogenesi immuno-mediata dell’Anemia Aplastica rende conto dell’alto 
tasso di risposte che i pazienti presentano ad un trattamento immunosoppressivo. 
Nel corso degli anni vari regimi di trattamento sono stati utilizzati, ma il più alto tasso 
di risposte è inevitabilmente associato all’impiego in combinazione di siero Anti-
linfocitario (preferibilmente ATG di cavallo) e ciclosporina. Regimi alternativi, 
includenti Ciclofosfamide o Alemtuzumab, rimangono attualmente limitati all’impiego 
in trial clinici. Tuttavia la maggior parte dei pazienti non può definirsi completamente 
curata con l’immunosoppressione, per il consistente tasso di risposte incomplete e/o 
recidive riscontrato, e per il rischio di progressione clonale osservato anche nei 
pazienti responsivi. Per questi motivi, probabilmente riconducibili al primitivo difetto 
intrinseco staminale sopracitato, il trapianto di cellule staminali attualmente 
rappresenta l’unica terapia in grado di curare definitivamente questi pazienti.  
Pertanto, in questo studio siamo andati ad indagare l’efficacia clinica e le 
dinamiche di ricostituzione immunologica di un regime di condizionamento ad 
intensità ridotta includente Fludarbina, Ciclofosfamide e Alemtuzumab 
(Condizionamento FCC) nel trattamento di questi pazienti. I risultati del nostro studio 
da un lato confermano gli ottimi risultati clinici del condizionamento FCC, per la 
ridotta incidenza di rigetto e GvHD, e la prolungata sopravvivenza globale e libera da 
eventi; dall’altro evidenziano una ricostituzione immunologica assolutamente 
peculiare, caratterizzata da una globale linfocitopenia post-trapianto nella quale 1) la  
rieducazione centrale dei linfociti T-CD4+, 2) l’espansione virus-mediata dei linfociti 
T-CD8+, 3) la presenza di cellule a fenotipo regolatorio (T-regs e B-regs) e 4) la 
costituzione di una condizione di chimerismo misto stabile creano una condizione di 
tolleranza post-trapianto refrattaria all’innesco di fenomeni immunologici 
potenzialmente nocivi (ad es. GvHD). 
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2. SUMMARY 
 
Aplastic anemia is a rare hematological disease, prototype of bone marrow 
failure syndromes, characterized by a progressive reduction of bone marrow stem 
cells that leads to classic histological finding of “fatty” or “empty” marrow. Clinical 
picture is dominated by bone marrow failure symptoms, such as fatigue, petechiae 
and/or fever that can rapidly deteriorate to potentially fatal bleeding, or life-
threatening blood sepsis. Aplastic Anemia commonly affects 1 to 2/106 individuals 
per year, with an estimated incidence about 2-3 times higher in Eastern countries. 
Although the etiology remains unknown in most cases, approximately one fifth 
of patients recognize a triggering event like: exposure to toxins (eg. Benzene) and / 
or drugs (eg. NSAIDs, gold salts, etc .) and / or viral agents (eg. Parvovirus B19, 
EBV, etc.). Rarely the disease follows an episode of self-limiting, sero-negative 
hepatitis. Regardless of this, pathogenesis of Aplastic Anemia is immune mediated, 
and is determined by cytotoxic action of T-lymphocytes against the hematopoietic 
stem cells, which eventually die by apoptosis. Due to this auto-immune mechanism, 
a quantitative and qualitative defect of stem cells is typically detectable. However, 
very recently, findings that stem cells of Aplastic Anemia patients may contain short 
telomeres, telomerase-genes complex mutations, or mutations in specific key genes 
of DNA epigenetic regulation system, have suggested that the functional damage of 
bone marrow does not derive only from an extrinsic immune-mediated mechanisms, 
but also form an intrinsic one, arising from a primitive genetic deficiency of stem cell 
compartment. 
The pathogenesis of immune-mediated Aplastic Anemia realizes high 
response rate that patients show after immunosuppressive treatment. Over the years 
several treatment regimens have been experimented, but the highest rate of 
responses is inevitably associated with combinative use of anti-lymphocyte serum 
(preferentially horse ATG) and cyclosporine. Alternative regimens, including 
Cyclophosphamide or Alemtuzumab remain limited to clinical trials. However, the 
majority of patients cannot be defined completely cured with immunosuppression, for 
consistent rate of incomplete responses or relapses, and for the risk of clonal 
progression, present even in responding patients. For these reasons, probably 
related to the primitive intrinsic stem cell defect aforementioned, hematopoietic stem 
cell transplantation is currently the only chance of long-term cure in these patients. 
In this study we investigated the clinical efficacy and immunological 
reconstitution dynamics of a reduced intensity conditioning regimen including 
Fludarabine, Cyclophosphamide, and Alemtuzumab (namely, FCC conditioning 
regimen) in the treatment of Aplastic Anemia patients. The results of our study clearly 
confirm excellent clinical results of the FCC-conditioning, for the reduced incidence of 
graft rejection and GVHD, and prolonged overall and event-free survival. Moreover, 
our result show clearly a peculiar immune reconstitution, where global post-transplant 
lymphocytopenia is associated with 1) central re-education of CD4+ T-lymphocytes, 
2) virus-mediated expansion of CD8+ T-lymphocytes, 3) presence of cells with a 
regulatory phenotype (T-regs and B-regs), and 4) establishment of a stable mixed 
chimerism status, that all together institute post-transplant tolerance, refractory in 
triggering potentially harmful immunological phenomena like GvHD. 
 
 
 
 
4 
 
3. INTRODUCTION 
 
3.1 Aplastic Anemia: from clinical features to pathogenesis of disease. 
 
Disease definitions. Aplastic anemia (AA) is the paradigm of bone marrow 
failure syndromes. It’s characterized by peripheral blood pancytopenia associated 
with an empty or fatty marrow as evidenced by bone aspirate and biopsy1, which 
directly demonstrates the contraction of the hematopoietic  compartment (Fig. 1). 
Even if most of cases remain idiopathic, a large amount of data support the idea that 
the empty bone marrow is determined by an auto-immune disruption of 
hematopoietic  stem cell (HSC), which leads to deficient hematopoiesis and disease 
related symptoms, defining AA as an autoimmune disease. Acquired forms of AA are 
far more frequent than constitutional ones, and typically affect young adults or elderly 
people, who present with peripheral pancytopenia in absence of other hematological 
diseases. The typical patient, young and previously well, presents with symptoms of 
mild bleeding and easy fatigue, but less frequently AA starts as fulminant illness, 
marked by continuous infections and recurrent hemorrhages, with a life-threatening 
condition2. Specific criteria define severity of disease (Moderate, severe or very 
severe)3 according to number of peripheral blood cytopenias and bone marrow 
cellularity (Table 1). 
 
 
 
 
 
Fig.1. Normal bone marrow (Left side) compared with AA marrow (Right side) 
 
  
 
Disease epidemiology. In almost all modern studies, sex ratio has been 
close to 1:1, which remains quite unusual for an immune mediated disease. Age of 
incidence shows a typical bimodal peak of distribution, with most of patients receiving 
diagnosis between 15 and 25 years, or over 60 years of age. Population-based 
studies have clearly established that disease incidence is relatively low, with an 
estimated rate of 2-5 person affected per million per year4.  
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Table.1. AA classification according to severity of disease
3
.  
 
However a marked geographic variation in disease incidence has been 
observed. In Europe and Western countries, a recent survey by Montanè et al 
(2008)5 has reported a incidence of 2.34/million that is similar to the rate of 2.0/million 
showed by the International Agranulocytosis and Aplastic Anemia Study in Europe 
and Israel (IAAAS, 1985)6, and to smaller national studies lead in France7, United 
Kingdom8, Scandinavia9 and Brazil10. In Asia and Far East countries, incidence of AA 
appears to be much higher: a large cohort study from Thailand  found a rate of 
3,9/million in the urban area of Bangkok11 and of 5/million in the rural area of 
Khonkaen11. Similarly a prospective survey of Chinese Epidemiologic Study Group of 
Leukemia and Aplastic Anemia12 reported an even higher rate of 7,4/million, showing 
how AA can rival with Acute Leukemia as admitting diagnosis in Haematological 
divisions of Chinese hospitals. Therefore, AA incidence appears to be 2- to 3-fold 
higher in Eastern than Western countries, with a frequency which hasn’t shown 
significant modifications across years. 
Etiology – Toxins and drugs. Even if most of cases remain of unknown 
origin, since the first case of AA was described an enormous amount of data on 
precipitating or causative factors has been accumulated in medical literature. 
Cytotoxic drugs and radiation are the best examples of factors that can directly injury 
HSC. In fact, although stem cells are more resistant to cytotoxic drugs, for most 
agents a dose-response relationship with the degree of stem cell damage can be 
established. Moreover, different studies have identified a list of chemicals and drugs 
whose exposure is associated with AA onset. Benzene13, for example, is the most 
widely studied and implicated amongst chemical toxins. The relationship with AA was 
initially brought to light by case series of workers exposed through their specific 
occupation: studies on American workers earlier in this century suggested that risk of 
AA was about 3% in men exposed to concentration higher than 300 ppm14, and in the 
more recent IAAAS6 study benzene was accounted for about 1-3% of AA recorded 
cases. Specific drug associations have been established in different population-
based study and have changed across time, mainly due to changes in drugs diffusion 
and utilization. Association with Chloramphenicol15, for example, that gained notoriety 
in the 1950s, and that for decades was considered the commonest cause of the 
disease, has progressively declined to the point that it has not been reported as 
significant risk factor in any recent systematic epidemiologic study of AA in Western 
countries5. Nowadays a long list of drugs associated with disease onset is available, 
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but mostly commonly seen associations are reported with gold salt (Relative Risk, 
RR of 29), anti-thyroid drugs (RR of 11), and Non-steroidal Anti-inflammatory Agents 
(RR of 8.2 for Indomethacin)15.  
Etiology – Viral infections. Among the potentially etiologic associations 
between environmental exposure and marrow failure other than drug or chemical 
toxins, viral infections have been linked to AA pathogenesis too. Parvovirus B1916, 
the causative agent for Fifth disease in the immunocompetent host, is associated 
with transient aplastic crises in chronic hemolytic anemias such as sickle cell 
disease, and cases of severe AA have also been reported in normal individuals 
during an acute episode of infection. More generally, cases of AA associated with 
HAV17, HBV18, HGV19, Epstein-Barr virus (EBV)20, or echovirus21 infections have 
been reported. Very recently retrospective observations about eight AA cases 
occurring during HIV22 infection have been reported, suggesting that AA could be a 
late rare complication of HIV infection too. Post-hepatitis AA23 is a stereotypical 
syndrome, where pancytopenia often presents two to three months after an acute 
attack of sero-negative, severe but self-limited, liver inflammation. This distinct 
variant has been commonly seen in 5-10%24 of ‘classical’ AA cases, typically 
occurring in adolescent boys and young men. The viral agent responsible for this 
syndrome has not been identified, but it is possible that at the time of overt cytopenia 
the viral infection is already cleared, with AA onset being mediated by lymphocytes 
recognizing a cross-reactive antigen in the marrow. Effective response to 
immunosuppressive therapy strongly suggest this immune mediated mechanism. 
Immune pathophysiology. Even if a putative inciting agent directly attacks 
the stem cell pool, causing a permanent depletion of HSC, generally the clinical 
presentation of cytopenia may be delayed for weeks or months, appearing just when 
a critically low stem cell number is reached. Similarly, an indirect damage of HSC can 
be sustained by an immune effector mechanisms, which may be triggered by viruses 
or by drug metabolites, and which may take time before becoming clinically evident. 
An analogous mechanisms may be postulated in the majority of cases of idiopathic 
AA, where an unknown initiating agent, probably through presentation or cross-
reactive triggering of neo-antigens, results in a breach of immune tolerance and in 
generation of an immune-mediated attack towards hematopoietic progenitors, 
leading to HSC consumption and functional impairment with subsequent 
pancytopenia (Fig. 2a)25. 
The responsiveness to immunosuppressive therapies (IST) remains the best 
evidence of an underlying immune pathophysiology of AA. In early laboratory 
experiments, removal of lymphocytes from aplastic bone marrows improved colony 
numbers in tissue culture, and their addition to normal marrow inhibited 
hematopoiesis in vivo26. Even if early stages of autoimmunity in AA have been less 
characterized, a large amount of studies have provided clear data on proximal events 
of immune-mediated marrow failure. The effector cells were identified by 
immunophenotyping as activated cytotoxic T-lymphocytes expressing Th1 cytokines, 
especially Interferon- (IFN-). CD8+ T-cells containing intracellular IFN-can now be 
measured directly in peripheral blood of AA patients27, and oligoclonal expansion of 
CD8+CD28- T-cells, defined by flow cytometric analysis for T-cell receptor (TCR) 
Vsubfamilies28, by spectratyping to detect skewing of Complementary Determining 
Region-3 (CDR3) length, and by sequencing of the CDR3 region to establish a 
molecular clonotype, has been detected in AA patients. In general, at presentation of 
disease patients demonstrate oligoclonal expansion of few Vsubfamilies, which 
diminish or disappear with successful therapy. Original clones re-emerge with 
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relapse, sometimes accompanied by new clones. Very occasionally a large clone 
persists in remission, suggesting establishment of immune tolerance (Fig. 2b)25. 
 
 
 
Fig.2. Interactions between blood counts, immune system and AA course.  
Modified from Young et al
25
.  
 
T-lymphocytes stem cell damage is mediated by direct cell-to-cell killing as 
well as by cytokine induced inhibition; the latter is documented by excess production 
of type I cytokines, especially IFN- and Tumor Necrosis Factor- (TNF-). T-Bet is a 
transcription factor that binds IFN- promoter and induce interferon genes translation 
in T-lymphocytes. Patients with AA show constitutive high expression of T-Bet 
gene29. Additionally, IFN- and TNF-activate the Fas-ligand30 and Tumor Necrosis 
Factor-derived Inhibitory Ligand (TRAIL)31, which play an important role in HSC 
inhibition by direct cell-to-cell adhesion. Such mechanisms may not be restricted to 
the primary target only, but may also attack innocent bystander cells, like stromal 
cells. Ultimately, these factors result in apoptosis32 of all existing bone marrow cells, 
through induction of different mechanism like Interferon Regulatory Factor 1 (IRF1), 
inducible NOS (iNOS) and production of nitric oxide (NO), and Fas- and TRAIL-
dependent pathway of cell death. Finally, IFN-, TNF-and Fas-L modulate the 
expression of their receptors through feedback mechanisms33, 34, and in this way they 
may enhance each other action (Fig. 3)25. 
Few putative auto-antigens have been identified as potential target of 
autoimmunity in AA, mainly through patients sera antibodies screening against 
human peptide library. Kinectin35, a widely expressed protein of cytoskeleton, bound 
to antibodies from about 40% of AA patients. In a smaller minority of patients, 
Diazepam-related Binding Protein-1 (DRBP-1)36, an enzyme essential for oxidation of 
fatty acid and distributed in different tissues, has been identified with same 
methodology. Which relevance in an essentially T-cell mediated pathology have 
these autoantibodies remain unclear. However, for Kinectin reactive cytotoxic T-cells 
can be generated in vitro and inhibit human HSC. Recently, a novel, autoreactive, 
CD1d-restricted, GPI-specific T-cell population37, enriched in a specific invariant 
TCRα chain (Vα21 sequence), has been documented in Paroxysmal Nocturnal 
Hemoglobinuria (PNH) patients. Since GPI-negative (not expressing surface protein 
with a Glycosyl-Phosphatidyl-Inositol anchor) hematopoiesis represents an escape 
mechanism to bone marrow failure in the pathogenesis of PNH, this finding suggests 
a potential role for a putative GPI-linked auto-antigen in the pathogenesis of acquired 
BMF in PNH37. 
a.  b. c. 
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Fig.3. T-cell activation and HSC killing in AA.  
Modified from Young et al
25
. 
       
 
Dysfunction of HSC in AA. Regardless the nature of injury, AA patients are 
characterized by a severe dysfunction of the HSC compartment; this defect has been 
deeply characterized in a both quantitative and qualitative fashion. Patients with 
acquired AA show a very low number of hematopoietic progenitors, as measured by 
flow cytometric CD34+ cell assessment or by in vitro colony assays38, 39, 40. By flow 
cytometry, CD34+ cells are reduced in all AA patients, and the contraction affects 
both committed, and immature CD34+/c-kit or CD34+CD38- progenitors41. The 
minimal number of colonies derived from committed progenitors in semisolid media 
reflect primitive HSC defect in these patients. Long-term culture-initiating cells (LTC-
IC) as well as cobblestone forming assay have been developed as surrogate of HSC 
activity assays42-44. The LTC-IC assay assesses cells capable of colony formation 
after 5 weeks in long-term bone marrow culture, and share the frequency, phenotype, 
and kinetic properties of true stem cells. Several studies indicate a profound 
deficiency in LTC-IC as well as cobblestone unit initiating cells in all patients with AA. 
At the time of clinical presentation, the number of LTC-IC is usually at least one log 
below the normal level45; combined with a reduction in total marrow cellularity to 
<10%, the stem cell number in AA is estimated to be reduced at least of two logs 
compared to healthy individuals45. Neither the LTC-IC number, nor that of colony 
forming cells, correlate with the blood counts, suggesting that in addition to the 
quantitative defect, a functional impairment may be present; this may also be 
extrapolated by the observation that the clonogenic capacity of an individual 
progenitor is lower than in normal. The reduced clonogenicity was demonstrated both 
on CD34+ cells46 (as number of colonies obtained from a purified CD34+ population) 
and on the putative stem cell LTC-IC (as number of secondary colonies assayed 
from LTC-IC in limiting dilution experiments)47. 
HSC compartment is affected by the pathophysiologic process operating in 
AA, whereas mesenchymal or even more immature pluripotent stem cells are likely 
functionally normal. Indeed, several studies48-50 have documented that marrow cells 
from AA patients are able to generate in vitro perfectly functional stromal layers, as 
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confirmed on cross-over experiments, which strongly support that stromal progenitors 
or early pluripotent stem cells are not affected in AA. This is also confirmed by the 
clinical observation that allogeneic stem cell transplantation is a highly successful 
therapy for AA, even if most stromal elements remain of host origin.  
Clonal events in AA. In last ten years several finding have enriched our 
knowledge of primitive HSC damage in AA, suggesting that the quantitative and 
qualitative defect exhibited by CD34+ cells may be not only related to the extrinsic 
attack of the immune system in bone marrow microenvironment, but may reflect also 
a primitive and potentially intrinsic genetic defect of HSC. First evidences of this 
conditions emerged from clinical finding that 10% to 15% AA patients can progress51, 
52 from a not malignant condition to clonal disease like PNH and Myelodisplastic 
Syndrome (MDS) or less frequently Acute Leukemia (Fig. 2c). Fifty percent or more 
of patients with AA have expanded PNH cells at diagnosis; most clones are small 
and do not lead to clinical symptoms of hemolysis or thrombosis, but in some cases 
classic PNH can be dominated by bone marrow failure symptoms, depicting the 
AA/PNH syndrome53. The large absence of GPI-linked surface protein in PNH cells, 
caused by mutation occurring in PIG-A gene sequence, which codify for an enzyme 
necessary for ligation of cell-surface protein to a GPI anchor, has generated the 
hypothesis that expansion of PNH clone could represent an escape mechanism to 
the immune attack responsible for of AA pathogenesis37. Indirect evidences for this 
derive from experimental observation that in AA patients PNH clone derived CD34+ 
cells preserve a proliferative capacity and does not express Fas-L, when compared 
with “normal” CD34+ cells54. 
Moreover, stereotypical patterns of aneuploidy have been observed in AA 
patients over time: monosomy 7 or trisomy 8 are the most characteristic, while less 
frequently translocation involving chromosome 3 and 13 are observed too55. Even if 
these anomalies can be rarely present at diagnosis, when differential diagnosis 
between AA and MDS with hypoplastic features may become challenging, their 
occurrence is generally observed as late event in AA history, from 10 to 15 years 
after initial diagnosis, sometimes even after a successful treatment with 
immunosuppression. In these case appearance of a cytogenetic abnormality is 
almost inevitable linked to clinical consequences, like profound progressive 
pancytopenia, leading to MDS and/or eventually to Acute leukemia (Fig. 2c)25.  
Telomere length in AA. Very interestingly, a significant telomere shortening 
has been reported in patients with AA, and telomere length in the lowest quartile has 
been correlated with a major risk for clonal evolution in general, and for monosomy 7 
in particular, with an estimated rates 5 to 6 times higher than in patients where 
telomere content is higher56. Telomeres are hexanucleotide (TTAGGG) repeats at 
chromosome ends, organized in secondary structure termed the T-loop, and 
associated with a protein complex collectively termed Shelterin. Telomerase is the 
ribonucleoprotein enzyme complex that synthesizes telomeres, that includes a 
reverse transcriptase, (encoded by gene TERT), an RNA template (encoded by gene 
TERC), and associated proteins that affect assembly, trafficking of Telomerase to 
telomeres, and Telomerase stability, such as Dyskerin (Fig 4). The cell is sensitive to 
critically short telomeres, which trigger DNA damage responses and lead to cell 
senescence or apoptosis, defining telomere length as a “mitotic cell clock” critical for 
survival. Telomeres erosions occur normally with aging, as well as under 
environmental circumstances where a regenerative stress and/or oxidative damage 
is present57.  Accelerated telomere shortening and attrition seen in AA may be a 
result of replicative stress imposed to the few remaining HSC after selective pressure 
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derived from immune system attack. Given this, telomere driven genomic instability 
would lead to chromosome loss and haplo-insufficiency of genes as on chromosome 
7, determining disease progression to MDS and eventually leukemia58.  
 
 
 
 
Fig.4. The Telomerase / Shelterin complex. 
  
      
However, marrow cells from patients collected years earlier before evidence of 
clonal disease may present both telomere loss and chromosomal aberrations many 
months or years prior of clinical evolution to MDS/AL. Intriguingly TERC, TERT and 
DCK159,60 mutations can be found in these individuals, making the historically clear 
distinction between constitutional and acquired aplastic anemia blurred due to the 
presence of mutations otherwise typical for congenital bone marrow failure 
syndromes (i.e. Dyskeratosis Congenita) in adult cases with no apparent family 
history and lacking classic physical anomalies. In these cases, telomere shortening 
may reflect defective ability of HSC to respond to stress due to intrinsic genomic 
deficiency in Shelterin/telomere complex, rather than a late clinical picture of a 
congenital disease. 
Gene mutations in AA. Finally two61,62 different groups have recently 
identified tanks to Next-Generation-Sequencing (NGS) analysis evidence for clonal 
hematopoiesis in AA. The majority of the mutations detected occur in genes involved 
in epigenetic regulation of DNA transcription, like ASXL1, DNMT3A and TET2, or in 
different genes like BCOR/BCOR-L1 and PIG-A. Various sets of mutations show 
distinct behavior and clinical effect; BCOR, BCOR-L1 and PIG-A mutant clones tend 
to disappear or remain small across time, are associated with a better response to 
IST, and predicted favorable outcomes. In contrast, clones carrying mutations 
in DNMT3A, ASXL1 and few other genes are more likely to increase in size over 
time, and are associated with a poorer response to IST, inferior overall survival, and 
with progression to MDS, Acute leukemia, or both. Very interestingly, these findings 
couple with recently published data63,64 showing that clonal hematopoiesis may occur 
in healthy individuals with older age, probably as result of Darwinian process which 
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select clones with survival advantage in the contest of ageing myelopoiesis. The 
presence of similar mutated clones in AA could indicate clonal hematopoiesis as a 
selective adaptation in the context of immune subversion/pressure secondary to 
disease onset. 
More intriguingly, data on clonal evolution, telomere length and gene mutation 
has finally started to depict a diversified and complex pathogenetic process, for which 
AA has to be seen not simply as simple autoimmune disease, but as complex stem 
cell disease where overlapping areas and gray-zones with other clonal malignant 
hematological disease exist (Fig 5).      
 
 
 
 
 
Fig.5. Venn diagram showing overlappin between AA and other clonal disease.       
 
 
 
 
 
3.2 Current concepts on treatment of Aplastic Anemia:                                                       
focus on immunosuppressive therapies  
Standard IST regimen in AA. The efficacy of immunosuppressive treatment 
(IST) in AA was firstly discovered in the early 60s, when observations from Mathè et 
al. highlighted how autologous recovery was possible in patients receiving Anti-
Lymphocyte Globulin (ALG) as part of conditioning regimen for allogeneic bone 
marrow transplant. After this report, two important randomized trial showed clearly 
the superiority of ALG based therapy on oral androgens and on supportive therapies 
in not transplanted patients, setting antiserum therapy as the standard IST for AA65.  
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The subsequent aim for clinicians was to obtain an increased response rate 
and a sustained response, preventing subsequent relapses, combining antiserum 
therapy with ALG or Anti-Thymoglobulin (ATG) with other immunosuppressant 
agents, like corticosteroids (i.e. methylprednisolone), androgens and cyclosporine-A 
(CyA). Only CyA, a calcineurin/NF-Kb inhibitor which impairs interleukin IL-2 
dependent T-cell activation and differentiation, has proven to be effective in these 
patients, as initially demonstrated by the German Aplastic Anaemia Group in a 
randomized trial66. In fact, the addition of CyA to ATG and steroids (utilized mainly for 
serum-sickness prophylaxis) increased the 6-month overall response rate from 46% 
to 70% in AA patients, possibly impacting long-term survival (even if no statistically 
significant difference was shown in this initial experience). After this study, and from 
90s on, ATG + CyA has become the most utilized IST for AA patients, with a reported 
response rate ranging between 50 to 65%, and with an expected overall survival rate 
at 1-year of 60%25. Even if in the majority of available studies, the overall response 
rate [complete response (CR) + partial response (PR)] does not exceed 70%, and 
has remained stable in the last twenty years, most recent studies have shown 
improved overall survival (above 80% at 1-year), independently from the initial 
response to IST67. Probably this effect has to be correlated with the improved 
supportive care, and better timing for salvage treatment, especially stem cell 
transplantation, that inevitably have an impact on long term overall survival. 
Impact of ATG type on IST results. An important point that needs to be 
clarified in antiserum therapy is that ATG/ALG is a heterologous anti-serum obtained 
by injecting human lymphocytes into animals. Therefore various ATG preparations 
exist, which can differ for stimulating antigens (peripheral lymphocytes, thymocytes, 
or even T-cell lines), and/or for host animal (either horse or rabbit). Most importantly, 
this differences hesitate in biological and clinical differences. The most dramatic 
biologic differences detected is the anticipated and more profound lymphocyte 
depletion observed in patients treated with rabbit ATG (r-ATG) compared with ones 
exposed to horse ATG (h-ATG), particularly for CD4+ T-cells, and including CD4+ T-
regulatory elements68. However, if this differences represent simply an association, 
or instead an explanation for h-ATG superiority in the clinical setting, remains still a 
matter of debate, especially if we consider that r-ATG was shown to be effective in 
rescuing a proportion of patients who previously failed h-ATG therapy.  
Most available data from large randomized clinical trials refer to polyclonal h-
ATGs, which have to be considered the gold standard for AA treatment. US and 
Japanese investigators utilized hATG (40 mg/kg per day, for 4 days; ATGAM; 
produced by Pharmacia US, or PFIZER Pharma), which is different from the h-ATG 
previously used in Europe (15 mg/kg per day, for 5 days; Lymphoglobuline; produced 
by Genzyme, or Fresenius Biotech). In the National Institutes of Health (NIH) 
experience69, the 3-year probability of survival was 96 % for h-ATG, versus 66 % for 
r-ATG, with a higher incidence of early deaths for infections in the r-ATG group. 
Similarly, the European Blood and Marrow Transplantation (EBMT) Group study70, 
which compared patients receiving r-ATG to matched historical controls treated with 
h-ATG (Lymphoglobuline), confirmed these differences, with h-ATG patients having a 
2 year-OS of 86% instead of 68% r-ATG patients survival rate. Even in the EBMT 
study, an higher incidence of fatal infection was observed in the r-ATG group, 
although at a later time-point (after day +100), when compared to the NIH study. 
Interestingly, a retrospective study71 on a Japanese population patients receiving r-
ATG showed similar response rates to the ones who received h-ATG treatment. 
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However, these results were not significant and 2-year, while at 10-year observed 
overall survival was again superior in the h-ATG group.  
Despite these evidences, h-ATG was withdrawn from the market after 2007 in 
Europe, leaving r-ATG, that formerly was a second-line choice in patients failing to 
respond to h-ATG, as the only available first line ATG for AA. Two r-ATGs are 
currently commercialized in Europe, but to the date clinical results with these agents 
are less robust for the lack of large randomized trials. In most cases, r-ATG was used 
as second-line IST (after initial h-ATG) to prevent side effects due to possible 
sensitization to horse proteins. In these setting, r-ATG resulted in an overall response 
rate up to 68% (in relapsed patients), suggesting an alternative use even in first line, 
whenever h-ATG preparation is not available. 
Intensification of standard IST in AA. Several attempts have been made to 
explore intensification of standard IST to improve response rates, increase stability of 
response and therefore reduce relapse rate. Essentially these trials explored two 
different options: 1) addition of a third immunosuppressant drug to the standard 
ATG+CyA regimen, or 2) usage of an alternative regimen including drugs different 
from Antiserum therapy. 
Intensification of immunosuppression has been explored adding high-dose 
corticosteroids, mycophenolate-mofetil (MMF), or rapamycin to standard treatment 
with h-ATG. Despite methylprednisolone at very high dosage (20 mg/kg/day) has 
shown some activities in AA patients, this condition did not show any improvement in 
response or survival rates. MMF, a purine synthesis inhibitor that is currently used 
both in bone marrow and solid organ transplantation to prevent GvHD or graft 
rejection, was tested in a prospective study conducted at NIH. Addition of MMF72 to 
ATG+CyA did not confer any benefit on either response rate (62% at 6 months) or 
relapse rate (37%, despite maintenance therapy with MMF) in comparison to 
historical data. Again, investigators at NIH assessed the potential benefit in AA of 
rapamycin/sirolimus (RAPA)73, a mammalian target of rapamycin (mTOR) inhibitor, 
which shares with CyA ability to block initial IL-2-dependent T-cell activation, and in 
addition to CyA is able to inhibit mTOR downstream signaling, affecting several 
intracellular pathways essential for cell-cycle progression and T-lymphocytes 
survival. In a randomized prospective trial, the addition of RAPA to the standard 
ATG+CyA regimen did not result in any improvement of haematological response in 
comparison to the control arm. One-year overall response rates observed were 
respectively 51% and 62%, with comparable relapse and survival rates in both arms. 
Alternative IST have been experimented with regimens including 
Cyclophosphamide and Alemtuzumab. A single phase 2 study conducted at the 
Johns Hopkins University testing high-dose Cyclophosphamide (50 mg/kg/die x 4 
days) for treatment-naïve AA patients was recently updated (2010)74; this study 
reported an actuarial overall survival and overall response rate respectively of 88% 
and 71%, with an actuarial event-free survival rate of 58% at 10-years. Unfortunately 
this treatment was associated with a long-lasting neutropenia, and severe fungal 
infections occurring at a rate of 18.2%. Similarly, in a randomized study conducted at 
NIH, directly comparing high-dose Cyclophosphamide to standard IST with h-
ATG+CsA, an excess of toxicity and death from invasive fungal infections were 
observed in the Cyclophosphamide arm, leading to an early termination of the study. 
A Chinese trial of “moderate” doses of Cyclophosphamide (30 mg/kg/die x 4 days) 
appeared attractive for the abbreviated period of neutropenia, little morbidity and 
mortality, and a response rate comparable to ATG + CyA regimen. Those results, 
combined with the recent drastic improvement of antifungal therapies justified further 
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investigation of moderate doses of cyclophosphamide. Unfortunately, when 
Scheinberg et al75 at NIH reported results of “moderate-dose” Cyclophosphamide 
(120 mg/kg) plus low-dose CyA in AA untreated patients, again the safety monitoring 
board of study recommended termination due to unacceptable toxicity, for excessive 
length of severe neutropenia (<0.2 × 109/L), and excessive rate of fungal infections, 
despite usage of aggressive antifungal prophylaxis. These data states clearly that 
Cyclophosphamide is not a competitive agent for the treatment of AA outside of 
clinical trials. 
Alemtuzumab, a monoclonal antibody that is able to induce lymphocyte 
depletion through specific killing of CD52-positive cells via both antibody-dependent 
cellular cytotoxicity and complement-mediated lysis, is another alternative 
immunosuppressant agent that have been explored in treatment of AA patients. A 
report from Risitano et al in collaboration with the EBMT has shown that an 
Alemtuzumab-based IST76 is feasible, safe and effective treatment option in AA. 
Preliminary data suggest a response rates not below standard IST regimen (58%), 
with easy re-treatment in case of relapse. Moreover, and differently from 
Cyclophosphamide, an acceptable rates of infections and toxicities has been 
observed.  
 
 
 
3.3 Allogeneic Stem cell Transplantation for Aplastic Anemia 
 
Rationale for Stem Cell Transplantation in AA. There are several reasons 
for which allogeneic hematopoietic stem cell transplantation (HSCT) at the current 
state remains the only definitive curative option in AA. First of all, even if most AA 
patients achieve a clinical benefit from immunosuppression, the quality of response is 
generally heterogeneous, with blood counts that could stay below normal values in 
responding patients too. With current IST regimens two third of patients shows a 
response after immunosuppression, that generally is equally distributed between CR 
and PR, but most of them (ranged between 25% and 50%) keep requiring long-term 
lower doses of CyA to maintain stable blood cells counts, and cannot be considered 
totally cured. Even when patients show a complete response, relapses are frequently 
seen, with a range in time that varies from months to years from IST 
discontinuation25.  
Secondly, about one third of patient doesn’t show any response to current 
standard h-ATG+CyA treatment and results to be refractory to IST; in these patients 
re-challenge with a second round of IST generally hesitate in dismal outcome for 
suboptimal responses and higher rates of infections. Molecular evidence on telomere 
length and gene mutations, as aforementioned above, suggest that in this category of 
AA a primitive intrinsic HSC damage develops early and persists independently from 
immune-dysfunction. In according with these observations, risk progression to clonal 
disease is not abolished after IST treatment, even when successful, and remain 
particularly higher in patients failing IST51,52.  
Given this, allogeneic HSCT remain the only long-term curative option able to 
guarantee a complete recover of bone marrow function in a disease where the stem 
cell compartment remain partially or totally dysfunctional even after IST.  
Allogeneic HSCT has been proposed as a potential treatment for AA since the 
early 60s, when initial reports described successful transplantation from geno-
identical twins (syngeneic HSCT)65. However, even in this setting became 
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immediately clear that intensity of immunosuppressive conditioning was able to 
increases chance of engraftment; therefore in subsequent years several attempts 
were made to intensify immune suppression in HSCT and finally ameliorate HSCT 
outcome. As result of this constant improvement, and based also on the outcome of 
IST, HSCT from an HLA-identical sibling donor (SIB) is now considered the treatment 
of choice for young AA patients65. Moreover, higher-resolution HLA-typing in recent 
years allowed a better donor selection and resulted in a significant improvement of 
survival even after HLA-matched HSCT from unrelated donor (MUD), making 
feasible access to HSCT even for patient where a familial donor was not available. 
Novel strategies of immunosuppression also allowed HSCT across the HLA-barrier, 
and HLA haplo-identical HSCT (Haplo) has proved to be successful in small series of 
AA patients. Finally, HSCT from cord blood (CB) units remains an alternative option 
for AA patients lacking a HLA-identical/well-matched donor.  
Irrespective of the feasibility of HSCT from different donor types, HLA-
matching remains the most relevant factor affecting the outcome in AA. In addition to 
this, success of allogeneic HSCT in AA is also largely affected by some transplant-
related factors, which include patient age, stem cell source, conditioning regimen, T-
cell depletion, graft rejection and graft-versus-host disease (GvHD).  
HSCT from HLA-identical SIB donor. Allogeneic HSCT from HLA-identical 
SIB donor result in long-term high survival rate in young AA patients. The standard 
procedure has been settled based on prospective studies carried mostly from the 
Seattle’s group, who explored in the context of HSCT for AA a conditioning regimen 
with high-dose cyclophosphamide (CY; total 200 mg/kg fractioned in 4 doses). The 
benefit of addition of ATG to CY (namely, Cy200-ATG conditioning) has been 
investigated in a prospective randomized trial, which enrolled 134 AA patients 
undergoing T-cell replete HSCT from sibling donors. Even if the CY200 + ATG arm 
showed a slight improvement in overall survival (80 vs 74% at 5 years), this was not 
statistically significant, likely due to not adequate statistical powering of the study77. 
Thus, the evidence to support the combination of CY200-ATG as conditioning 
regimen comes mainly from previous non-randomized trial78, where this regimen 
resulted in improved survival with reduced chronic GvHD rates, as compared with 
historical controls who have been conditioned by CY alone. However a clear point 
that need to be specified is that current survival reported with Cy200-ATG range from 
65% to 95%78,79, according to patient age, and that this conditioning regimen is 
associated with a very low incidence of second tumors and preservation of fertility.  
Alternative T-cell depletion with lymphodepleting agent other than ATG like 
Alemtuzumab have been explored, and actually the role of in vivo conditioning with 
ATG or Alemtuzumab for HLA-identical SIB HSCT remain a controversial point of 
debate. A randomized trial failed to show a survival advantage for patients receiving 
ATG in the conditioning regimen when compared with controls80, while an EBMT81 
retrospective study, on much larger number of patients, has shown a clear advantage 
for ATG-treated patients on Alemtuzumab ones. A recent UK study82 comparing the 
use of ATG with the use of Alemtuzumab for in vivo T-cell depletion (including HSCT 
from SIB, MUD and mismatched donors) showed that engraftment failure rates were 
inferior in the Alemtuzumab group when compared to the ATG group (9% vs 11%, 
respectively), with a similar survival outcome for sibling (91% vs 85%, respectively), 
and with a lower risk of chronic GvHD observed in the Alemtuzumab group (11% vs 
26%). An additional way is to use “Alemtuzumab in the bag,”83 producing ex vivo T-
cell depletion: the method is probably not widespread, but may lead to significant 
protection against chronic and acute GvHD. Given this, the standard conditioning 
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regimen for patients with acquired AA undergoing an HLA-identical sibling transplant 
remains remain CY200 plus ATG or Alemtuzumab as T-depleting agents. 
Independently from type of T-cell depletion, or presence of other HSCT 
outcome predictors, age at transplant contributes to the successful outcome and long 
term survival from HSCT. Older AA patients, with longer diagnosis-to-HSCT interval, 
and long history of previous IST and blood transfusions present a dismal outcome 
when compared with the youngest one84. The actual causes of treatment failures are 
not different from those seen in younger patients, including graft failure and mostly 
GvHD and its further complications (i.e., infections). In keeping with observations 
from HSCT in other settings (i.e., acute leukemias), different groups have 
investigated the possibility to reduce the intensity of the conditioning regimen, 
possibly sparing early toxicity which may trigger GvHD and other transplant-related 
complications. For this reason, Fludarabine (FLU) -based regimens have been also 
introduced in older adults85. In a retrospective EBMT study86, patients older than 30 
receiving FLU-based regimens were compared with a matched paired group of 
patients conditioned with Cy200-ATG over the same period of time (1998–2007): 
patients conditioned with FLU had a higher probability of OS than the control group, 
when adjusting for recipient’s age, possibly related to a trend toward a reduced 
incidence of graft failure in patients receiving FLU (0% vs 11%), whereas no 
difference was observed regarding incidence of GvHD. In a more recent analysis87 of 
the EBMT, the effect of age was combined with conditioning regimen in transplants 
from HLA-identical siblings, in the period 2001 through 2010 (See fig.6).  
 
 
 
 
Fig.6. Effect of age combined with conditioning regimen in AA transplants from 
HLA-identical siblings (2001-2010).       
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Survival of patients aged 1 to 20 years was 89%; survival of those aged 21 to 
40 was 76%; survival of patients older than 40 receiving a FLU-based regimen and 
ATG or Alemtuzumab in the conditioning regimen was 74%; survival of patients older 
than 40 receiving a FLU-based regimen, but no ATG and no Alemtuzumab, was 
64%; and survival of those older than 40, not receiving a FLU-based regimen, and no 
ATG nor Alemtuzumab, was of 54%. This study suggests that survival can improve in 
patients older than 40 years if appropriate modifications are made in the conditioning 
regimen, using a combination of FLU and intermediate dose of Cy to reduce 
conditioning intensity. Finally, as for Cy200-ATG, the replacement of ATG with 
Alemtuzumab88 seems to result in even better outcomes, eventually providing an 
additional conditioning regimen to be considered as standard of care. Determining 
the upper age limit for eligibility to transplant in AA remains a difficult issue. It would 
seem reasonable to restrict transplantation from identical siblings to AA patients who 
are younger than 60 years, using reduced intensity conditioning regimens, as 
described above. 
Three different stem cell sources, namely bone marrow (BM), peripheral blood 
stem cells (PBSC), and granulocyte colony–stimulating factor (G-CSF)–mobilized BM 
(primed-BM), can be considered as graft source for HLA-matched transplantation 
from SIB donor. A first combined EBMT/Center for International Blood and Marrow 
Transplant Research (CIBMTR)89 analysis has shown a significant survival 
advantage for BM grafts in young patients (<20 years) but not in older patients (≥ 20 
years): this study also confirmed the increased risk of chronic GvHD for recipients of 
PBSC grafts. In 2012 the EBMT published a second analysis90 on a much larger 
number of patients who received a first matched sibling transplant between 1999 and 
2009, with BM or PB as a stem cell source. The conclusions of this study were 
unequivocal: PB grafts from HLA-identical siblings, when compared with BM grafts, 
were associated with a greater risk of acute grade II to IV GvHD (17% vs 11%) and a 
greater risk of cGvHD (22% vs 11). The survival disadvantage for PB in comparison 
with BM was significant in patients aged 1 to 19 years (76% vs 90%) and in those 
aged 20 years and older (64% vs 74%); this was true also for those older than 50 
years (39% for PB vs 69% for BM). In an additional study91 comparing BM, PB, and 
primed-BM, acute and chronic GvHD were again higher in PB graft recipients, and 
there was no advantage for G-CSF–mobilized BM in terms of engraftment and 
survival. Given this, BM should be the stem source of choice for HLA-identical stem 
cell transplants in patients with AA, while the use of PB should be discouraged due to 
association with worse survival and increased risk of GvHD, especially chronic. 
Graft rejection, an historical problem in HSCT for AA, is now not frequent in 
patients who go directly to transplant, and with a modest transfusion burden, likely 
due to a beneficial loss of exposure to immunogenic products from fewer donors 
(leukocyte-depleted erythrocytes, platelet collected by cyto-apheresis). Conditioning 
regimens who do not include irradiation in sibling transplant regularly achieve 
sustained engraftment in more than 96% of cases treated with Cy200-ATG regimen. 
Similarly, FCA regimen has ensured acceptable engraftment rates in older patients 
with AA without irradiation. The use of chimerism92 studies using short tandem repeat 
(STR) method, has been a major advance in our understanding of how 
donor/recipient myeloid and lymphoid cells interact. In a study93 on 94 AA 
transplants, patients were classified as: 1) complete donor chimeras (43%), 2) 
transient mixed chimeras (16%), 3) stable mixed chimeras (20%), 4) progressive 
mixed chimeras (15%), and 5) early graft rejection (5%). This study showed that 
mixed chimerism occurs frequently in a large proportion of patients, especially early 
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after HSCT, and that kinetics of sequential chimerism is a predictor of outcome, with 
progressive mixed chimeras at higher risk of rejection or disease relapse. Treatment 
of mixed chimerism has not been standardized in AA. Mixed-chimerism associated 
with declining peripheral blood counts may be treated with low doses of donor 
lymphocyte infusions (DLI), while maintaining GvHD prophylaxis with cyclosporine. 
Unfortunately there are no reports on this approach, and the use of DLI for mixed 
chimerism continues on a patient-to-patient basis. Caution must be exercised with 
DLI dosing because of the potential risk of lethal GvHD in these patients. 
HSCT from HLA-Matched Unrelated Donor. The outcome of MUD HSCT for 
patients with AA has constantly improved over the last 15 years. Better selection of 
HLA-matched donors, with introduction of high resolution HLA screening94, and 
adoption of reduced intensity conditioning regimen, including FLU-based 
chemotherapy protocols and low-dose Total-Body Irradiation (2 Gy TBI) in adults95, 
improved general overall survival in this setting, reaching currently reported level 
above 75%. Results of MUD HSCT have improved so much that now treatment 
guidelines2 for AA consider it as a recommended second line treatment in adults 
failing to respond to one course of IST, while in children where a SIB donor is not 
available, a consistent growing amount of studies suggest that it may be considered 
even as first line treatment for severe and very severe AA. 
Different centres match either for A, B, C and DRB1 at the allelic level, looking 
for 8/8 matched donors, or for DQ looking for a 10/10 match. In a recent EBMT 
analysis96 was showed that an effect of mismatching (<8/8 vs 8/8 match) is evident 
only for patients prepared with FLU-CY and ATG (FCA), but not for patients receiving 
FCA supplemented with low-dose TBI (FCA-TBI). Therefore, an 8/8 (A, B, C and 
DRB1) matched donor would be ideal, but a 7/8 (or 9/10) match would probably be 
also acceptable and recommendable if low-dose TBI is added to conditioning 
regimen. The dose of CY for FCA was originally set at 300 mg/m2. This was 
associated with a significant risk of rejection, so the current indication is to decrease 
the dose of CY to 120 mg/kg. Using the FCA regimen, EBMT study96 showed that 
rate of acute GVHD grade II–IV was low (18%), with chronic GVHD more frequent, 
as expected, when TBI 2 Gy was added to overcame HLA-mismatching (50% vs 
27%). This was particularly true when PB was used as a source of stem cells. In 
particular, risk of extensive chronic GVHD is 3% for BM, and of 20% for PB. 
A study of the CIBMTR97 has compared BM and PB in UD transplants for 
acquired AA: 296 patients received either BM or PB from unrelated donors, matched 
at HLA-A, -B, -C, and -DRB1 level. Hematopoietic recovery was similar after PB and 
BM transplantation. Acute grade II to IV GvHD was more frequent in PB than in BM 
(48% vs 31%). cGvHD risks were not significantly different after adjusting for age at 
transplantation. Mortality, independent of age, was higher after PB compared with 
BM transplantation (76% vs 61%). The investigators concluded that in UD 
transplants, similarly to HLA-identical siblings, BM is the preferred graft source in 
SAA. Finally, a general consensus exist on the concept that a marrow cell dose 
ranging between 3 to 4x108/kg seems to allow optimal outcome. Sib HSCT, Campath 
is emerging as an alternative option to ATG (FCC regimen)88. Using FCC, the risk of 
acute GVHD is 14% and chronic GVHD 4%, suggesting a potential low incidence of 
GVHD with this conditioning regimen. 
Graft failure remain a clinical issue in MUD HSCT. Using the FCA96 regimen, 
cumulative incidence of graft failure was 17% in the EBMT study. Patients with a 
longer interval from diagnosis to transplant (>2 years) had a trend for a higher risk of 
graft failure (22%) when compared with patients grafted <1 year (12%), or between 1 
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and 2 years from diagnosis (14%). Five-year survival were respectively of 87% and 
55% for patients grafted within or beyond 2 years from diagnosis. Comparable graft 
failure rates were reported with FCC regimen even for the MUD HSCT setting. 
Alternative donor HSCT for AA. The use of CBT in AA has not been 
systematically investigated. The largest study was reported by the EUROCORD98 
and EBMT, and included 71 patients grafted from either a single or double CB units. 
In this study, the outcome was not excellent (3-year survival 38%) mostly due to graft 
failure: indeed, neutrophil recovery at 2 months was achieved in 51% of patients 
only, and obviously associated with the number of nucleated cells contained in the 
CB unit. Sixty-eight percent of the patients received a Flu-based conditioning 
regimen; all the patients receiving a fully myeloablative conditioning regimen with TBI 
died. Similar outcomes were reported from the Japanese Registry; the possible 
beneficial effect of a reduced intensity conditioning regimen was also confirmed in a 
smaller series.  
Haplo-identical HSCT remain an interesting option for AA, considering the fact 
that the great majority (if not all) patients should have some haplo-identical donors. 
Furthermore, the interest for this strategy has been revived by the recent seminal 
studies from the Johns Hopkins group in Baltimore, who successfully exploited post-
transplant immunosuppression using high-dose CY. Historically, results with Haplo-
identical HSCT has been disappointing; a recent EBMT99 survey reported the 
outcome of 73 AA patients transplanted between 1976 and 2011, showed a 3-year 
overall survival of only 37%, largely as a result of lack of stable engraftment and/or 
development of GvHD or other transplant-associated complications. On the contrary, 
additional promising data were recently reported by the King’s College group, who 
reported stable engraftment in six out eight AA patients grafted from a HLA haplo-
identical donor using the Johns Hopkins protocol; notably, only one patient 
developed grade II acute GvHD, and no chronic GvHD was reported, irrespective of 
the fact that PBSC was used as stem cell source. Based on these data, CBT and 
Haplo-HSCT are actually not recommended for AA patients, and their use should be 
limited within prospective trials, or at least in few experienced transplant centers. It 
has to be remarked that in this specific HSCT setting, selection of an alternative 
donor should rule out the presence of HLA-antibodies specific for donor HLA 
antigens, given the highest risk of graft rejection highlighted. 
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4. AIMS OF THE STUDY 
 
In 2011 Marsh et al88 reported that a conditioning regimen including 
Fludarabine 30 mg/m2 given daily x 4, Cyclophosphamide at doses of 300 mg/m2 
given daily x 4, and Alemtuzumab (the humanized anti-CD52 antibody Campath1-H), 
namely FCC, was associated with sustained engraftment and excellent outcome in 
AA HSCT both from SIB and MUD donors. Very interestingly, rate of engraftment 
was comparable with ones reported in literature, despite persistence of stable mixed 
chimerism in CD3+ T-cell fraction for a consistent percentage of patients. Most 
notably, rate of acute GVHD was of 13.5% (only grades I-II), and rate of chronic 
GVHD only of 4%. Finally, factors significantly associated with inferior outcome in 
HSCT for AA, like older age at transplant, longer interval from diagnosis to HSCT, 
and use of PBSC as a source of stem cell, did not impact significantly in this cohort. 
Presumably these clinical features, including low incidence of GVHD, were related to 
in vivo T-cell depletion with Alemtuzumab, and the establishment of mixed donor/host 
chimerism in the CD3+ T-cell compartment, suggesting that FCC may work as an 
“immune-ablative” conditioning regimen in adults with AA. 
Nevertheless, some criticism in this study were present. Firstly, data collected 
were mainly retrospective, with an heterogeneity in patient cohort derived from the 
multicenter nature of the study, with different dosage of Alemtuzumab used per 
patient. Secondly, patients follow-up was relatively short, with a median time of 
observation reported of 18 months, that remained quite unsatisfactory in providing 
data on long term survival and the intriguing topic of the persistent CD3+ mixed 
chimerism.  
Finally, even if the same authors defined FCC as an immune-ablative 
conditioning regimen, no data were provided about immune reconstitution after this 
type of HSCT, with eventual correlation with excellent outcome in AA. 
 
Given this, aims of this study were: 
 
 To confirm excellent clinical outcome of FCC HSCT for AA patients, 
particularly in terms of graft failure and GvHD incidence, and long term 
survival. 
 
 To analyze immune reconstitution in this specific setting of patients, providing 
correlation with clinical outcome. 
 
 To analyze long term chimerism trend and impact of persistent mixed chimera 
on immune phenomena after HSCT, especially graft failure and GvHD. 
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5. PATIENTS, MATHERIALS AND METHODS 
5.1 Study population 
 
All patient receiving HSCT for AA at King’s College Hospital from January 
2007 to June 2015 were given access to the study. During this period, 45 patients 
were enrolled (Male/Female, 28/17). Median age at transplantation was of 32 years 
(Range 15 - 63), with 14 (31.1%) patients older than 50 years. AA was idiopathic in 
91.2% of cases. HSCT was performed after immunosuppressive therapy in 33 
(73.3%) patients, with ATG + CyA as preferred regimen. At diagnosis, a PNH clone 
was detected by flow cytometry in 21 (46.6%) patients. Baseline patients 
characteristics before HSCT are summarized in table 2.  
According to Marsh et al, FCC conditioning regimen was administered as 
follow: Cyclophosphamide 300 mg/m2 IV daily x 4 days, given from day −7 to −4; 
Fludarabine 30 mg/m2 IV daily x 4 days, given from day −7 to −4; Alemtuzumab was 
given 0,2 mg/Kg IV or SC daily x 5 days, from days −7 to −3. Stem cells were given 
at day 0, both from BM or PBSC source, according to investigator choice and donor 
availability. TBI (total dosage of 2 Gy) was added to conditioning protocol in 7/8 HLA 
mismatched MUD transplant to improve engraftment according with previous 
observations. 
Post-HSCT GvHD prophylaxis consisted in CyA (starting dosage 2.5 mg/kg IV) 
from day −1 on, and titrated to plasma trough levels of 200-300 ng/mL. Oral CyA was 
substituted when a good oral intake was achieved, and continued for 12 months, with 
tapering at 9 months in presence of stable hematologic parameters and without 
declining mixed donor chimerism, and complete suspension at one year after HSCT, 
in absence of any sign of GvHD.   
Supportive care with irradiated blood products and antimicrobial treatment 
were provided according to institution practices and EBMT recommendations for AA 
patients. All patients were screened for CMV and EBV infections/reactivation at least 
weekly for the first 3-6 months using PCR-based assay. 
Neutrophil engraftment was defined as the first of 3 consecutive days with an 
absolute neutrophil count (ANC) ≥0.5 x 109/mmc, unsupported by G-CSF. Platelet 
engraftment was defined as the first of 3 consecutive days with a platelet count ≥ 
20x109/mmc, without platelet transfusion support for 7 preceding days. Patients were 
considered evaluable for engraftment if they survived more than 21 days after 
transplantation. Primary graft failure was defined as the absence of neutrophil count 
≥0.5x109/mmc on 3 consecutive days, and late graft failure as recovery followed by 
recurrent pancytopenia with a hypocellular BM in the absence of severe GVHD. 
Acute and chronic GvHD was diagnosed on clinical grounds with histopathologic 
biopsy where possible and graded according to published NIH criteria.  
Study protocol was approved by King’s College internal review board and 
Ethical Committee, and was conducted in accordance with the Declaration of 
Helsinki. All patients signed separated informed consent form for inclusion in clinical 
treatment group, and for collection of biological samples. 
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Table 2. Patients characteristics, FCC cohort      
Number of patients 
Median age (range) 
Number of patients aged > 50yr 
45 
32 (15 – 63) years 
14 (31.1%) 
M : F 28 : 17 
Aetiology of aplasia 
- Idiopathic 
- Post-hepatitic (seronegative) 
- Eosinophilic fasciitis 
- Coeliac disease 
 
41 (91.2%) 
2 (4.4%) 
1 (2.2%) 
1 (2.2%) 
IST previous HSCT 
- Matched sibling (MSD) 
- Unrelated donor (UD) 
 
6 of 12 (50%) 
27 of 33 (81.8%) 
Number of patients HLA alloimmunised 11 (24.4%) 
Number of patients with PNH clone 
 
Median PNH clone size: 
- granulocytes 
- monocytes 
21 (46.6%) 
 
 
2% (range 0.02 – 40%) 
2.85% (range 0.01 – 32%) 
 
 
 
 
5.2 Immunophenotypic analysis 
 
PB samples for immune reconstitution analysis were collected from patients at 
day +30, +60, +90, +180 and + 360 after HSCT. Peripheral Blood Mononuclear Cells 
(PBMC) were separated by a gradient centrifugation with Ficoll-Paque Plus system 
(GE Healthcare, Sweden), and aliquots were stored frozen in liquid nitrogen after 
DMSO resuspension to preserve viability. When prepared for Immunophenotypic 
analysis, PBMCs were thawed rapidly in 37ºC water bath, transferred to RPMI1640 
colture medium with 10% fetal calf serum (FCS) and 1% Penicyllin/Streptomycin 
(P/S), and then centrifuged at 1300 rpm (300g) for 10 minutes at room temperature, 
to remove DMSO. Cell viability was subsequently assessed by cell counting in 
Neubauer chamber after L/D staining with trypan blue. A minimal amount of 0.5 to 
1x106 cell, with viability >90%, was accepted to proceed for staining with specific 
antibody panel. After cell counting, two additional washing step were performed with 
resuspension in PBS only (in the absence of any protein) and centrifuge at 1300 rpm 
(300g) for 10 minutes at room temperature. 
An appropriate volume of fluorochrome-labeled monoclonal antibodies cocktail 
was then added to relevant sample, according to specific lymphocyte subset, for 
surface staining. An intracellular Foxp3 staining step was additionally performed after 
permeabilization (with BD Biosciences Cytofix/Cytoperm solution), according to the 
manufacturer’s instructions, when needed.  
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Data on fluorochrome-coniugated antibodies, including clone type, 
fluorochrome, supplier and amount used according to manufacturer’s instructions are 
listed in table below (Table 3 a,b,c,d): 
 
 
Panel Parameter Detector 
L per 
0.5x10^
6
 
cells Supplier Clone 
NK, B, 
T-cells 
CD3 VioGreen V525 1 Miltenyi Biotech BW264/56 
CD56 PerCP-Cy5.5 B710 2.5 BD Biosciences B159 
CD16 eFluor 450 V450 2 eBioscience CB16 
CD19 APC R670 10 BD Biosciences HIB19 
Pan gd TCR PE YG586 2 eBioscience B1.1 
TCR V g9d2 FITC B530 1 
Beckman 
Coulter 
No carry 
L/D eFluor 780 
R780                 
dump 
channel for 
Monocyte 
and L/D 
1 eBioscience No carry 
CD14 APC- eF 780 2.5 eBioscience 61D3 
CD45 AlexaFluor 700 R730 1 Biolegend HI30 
Table 3a. Staining cocktail for characterization of NK, B-cells and T-cells. 
   
 
Panel Parameter Detector 
L per 
0.5x10^6 
cells Supplier Clone 
T-cell 
subsets 
CD3 VioGreen V525 1 Miltenyi Biotech BW264/56 
CD4 PerCP Cy5.5 B710 2.5 eBioscience RPA-T4 
CD8 eFluor 450 V450 2.5 eBioscience RPA-T8 
CD45RA APC R670 10 BD Bioscience UCHL1 
CD27 FITC B530 2.5 eBioscience 323 
CD62L PE YG586 10 BD Biosciences DREG-56 
CD31 PE-Cy7 YG780 2.5 Biolegend WM59 
CD14 APC-eFluor 780 
R780                 
dump channel 
2.5 eBioscience 61D3 
L/D eFluor 780 1 (all cells) eBioscience No carry 
CD45 Alexa Fluor 700 R730 1 Biolegend HI30 
Table 3b. Staining cocktail for characterization of T-lymphocytes (T-cells) subsets in PBMCs. 
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Panel Parameter Detector 
L per 
0.5x10^
6
 
cells Supplier Clone 
 
T-regs 
 
CD3 VioGreen V525 1 Miltenyi Biotech BW264/56 
CD4 eFluor 450 V450 1 eBioscience RPA-T4 
CD27 FITC B530 2.5 eBioscience 323 
CD25 APC R670 5 BD Bioscience BC96 
CD45RA PE YG586 10 BD Bioscience HI100 
CD127 PE-Cy7 YG780 2.5 eBioscience RDR5 
Foxp3 PerCP Cy5.5 B710 1.5 eBioscience PCH101 
L/D eFluor 780 R780 1 (all cells) eBioscience No carry 
Table 3c. Staining cocktail for characterization of T-regulatory cells (T-regs). 
 
 
 
 
 
Panel Parameter Detector 
L per 
0.5x10^
6
 
cells Supplier Clone 
 
B-cells 
 
CD19 APC R670 10 BD Bioscience HIB19 
CD27 PerCP-Cy5.5 B710 2.5 BD Bioscience MT271 
CD38 FITC B530 10 BD Bioscience HIT2 
CD24 PE YG586 10 BD Bioscience ML5 
IgM Pacific Blue V450 5 Biolegend G20-127 
IgD APC-H7 R780 2.5 BD Bioscience IA6-2 
Table 3d. Staining cocktail for characterization of B lymphocytes (B-cells). 
 
 
 
Nine-color analysis was performed by flow cytometry using a BD LSR-
Fortessa FACS cell analyzer (BD Biosciences). A minimum of 1x105 events were 
acquired per sample; acquired results were analyzed with FlowJo software 
(TreeStar). Lymphocytes subset were defined as per recently updated Human 
Immunophenotyping Consortium reported by Finak et al. (see table 4). Lymphocytes 
numbers were calculated from percentage values, based on an absolute lymphocyte 
count of the blood sample obtained using an automated leukocyte counter. 
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Lymphocytes Subset Phenotype 
B-cell CD45+ CD19+ CD3-  
Transitional (T1&T2)  CD19+ CD3- CD24-bright CD38-bright IgM-bright IgD-bright 
Naive CD19+ CD3- CD24-int CD38-int IgM-int IgD-int 
Memory CD19+ CD3- CD24-bright CD38-dim IgM-int IgD-dim 
NK-cell CD45+ CD3- CD56+ CD16+ or CD3- CD56-dim CD16+  
Gamma/delta T-cells CD45+ CD3+ pan gdTCR+ 
Vg9d2 T-cells CD45+ CD3+ pan gdTCR+ Vg9d2 TCR+ 
CD4+ T-cell CD3+ CD8- CD4+  
CD4+ Naïve  CD3+ CD4+ CD45RA+ (or CD45RO-) CD27+ 
CD4+ Memory CD3+ CD4+ CD45RA- (or CD45RO+) CD27+ 
CD4+ Effectors CD3+ CD4+ CD45RA- (or CD45RO+) CD27- 
CD4+ Terminal effectors CD3+ CD4+ CD45RA+ (or CD45RO-) CD27- 
CD4+ Recently Thymic 
Emigrants 
CD3+ CD4+ CD45RA+ CD31+ CD62L+ 
CD4+ Regulatory T-cell CD3+ CD4+ CD25-high CD27+ CD127-low Foxp3+  
CD8+ T-cell CD3+ CD4- CD8+ 
CD8+ Naïve  CD3+ CD4- CD8+ CD45RA+ (or CD45RO-) CD27+ 
CD8+ Memory CD3+ CD4- CD8+ CD45RA- (or CD45RO+) CD27+ 
CD8+ Effectors CD3+ CD4- CD8+ CD45RA- (or CD45RO+) CD27- 
CD8+ Terminal effectors CD3+ CD4- CD8+ CD45RA+ (or CD45RO-) CD27- 
Table 4. Lymphocytes subset defined as Human Immunophenotyping Consortium (2016). 
 
 
 
5.3 Functional B-cell assay for IL10-production  
 
For characterization of IL10 B-cell production, PBMCs were co-coltured with 
irradiated CD40L+ L-cells for 12 hours (Ratio 1:10). Phorbol myristate acetate (PMA) 
(50 ng/mL), Ionomycin (250 ng/mL) (Sigma-Aldrich), and Brefeldin A (5 µg/mL, 
GolgiPlug; Sigma-Aldrich) were added for the last 6 hours of the culture. Cells were 
harvested, washed in staining buffer, and incubated  as previously described with 
CD19-APC, CD38-FITC and CD24 PE (BD Bioscience) for surface staining. was 
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obtained. IL-10 production was assessed on gated CD19+ B cells by intracellular 
cytokine assay. Cells were fixed/permeabilized (eBioscience) and stained with 
PerCP-Cy5.5-conjugated IL-10. At this stage, 20 µL of FcR blocking reagent (Miltenyi 
Biotec) was added. All data were acquired using BD-FACSCalibur (Becton 
Dickinson) and analyzed with FlowJo software. 
CD40L-transfected liver mouse fibroblasts (CD40L-cells) and non-transfected 
control fibroblasts (L cells) (kindly provided by Dr L Barber, King’s College, London, 
UK) were grown in RPMI 1640 with 10% FCS.  
 
 
5.4 CMV tetramer staining 
 
Tetramer staining and peptide library functional assay were used to identify 
CMV specific T-lymphocytes. Pro5®, a PE fluorochrome-conjugated MHC class I 
pentamer (Proimmune, Oxford, UK), containing an HLA-A*0201-restricted NLV 
peptide (NLVPMVATV - pp65, 495–503) was used for identification of CMV peptide-
specific CD8+ T-cells. PBMCs were stained with appropriate pentamer amount (15 
min at ambient temperature, 10 l per 1-2x106 cells), washed and then incubated (30 
min, 4°) together with anti-CD8 PerCP-Cy5.5 and anti-CD4 APC antibodies, in order 
to identify specific T-cell subpopulations. 
 
 
 
5.5 Chimerism analysis 
 
Samples (PB and BM) for chimerism study were collected from patients after 
HSCT at day +30, +60, +90, +180, and then annually. Chimerism was assessed in 
isolated peripheral blood CD3+ T-cell and CD15+ granulocyte populations, as well as 
unfractionated bone marrow samples. Density gradient centrifugation was employed 
to separate low and high-density cells from whole peripheral blood samples (Density 
1·077 g/ml) (Histopaque; Sigma Diagnostics, St Louis, MO, USA). An AutoMACS 
magnetic cell separator (Miltenyi Biotec Ltd, Surrey, UK) was used to isolate the cells 
(>95% purity) from peripheral blood samples and DNA was extracted using the 
QIAamp DNA Blood Mini Kit (Qiagen Ltd, Crawley, UK). Fifteen polymorphic short 
tandem repeat (STR) loci (Penta E, D18S51, D21S11, TH01, D3S1358, FGA, TPOX, 
D8S1179, vWA, Penta D, CSF1PO, D16S539, D7S820, D13S317 and D5S818) plus 
the sex-determining Amelogenin loci (PowerPlex®; Promega Corp, Madison, WI, 
USA) were amplified to provide a genetic profile for pre-transplant donor and 
recipient samples. Informative alleles were identified and used to assess donor 
engraftment. The samples were electrophoresed using polyacrylamide gel 
electrophoresis on an ABI Prism 377 DNA sequencer and analysed using Genescan 
2·0 software (Applied Biosystems, Foster City, CA, USA).  
Quantification was carried out using the area under the peaks; cell dilution 
studies found the sensitivity of this methodology to be approximately 5%. Therefore, 
full donor chimerism (FDC) was defined as the presence of >95% donor 
haematopoietic cells, while MDC was defined as presence of 5–95% donor cells 
post-HSCT. Patients who showed mixed donor-recipient chimerism, but who 
subsequently reverted to full donor chimerism were classified as having transient 
mixed chimerism. Declining donor chimerism was defined as a 10% or greater 
increase in recipient chimerism on 2 consecutive measurements. 
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5.6 Cell sorting for chimerism analysis of specific cell subsets 
 
PBMCs from frozen aliquots were labeled as previously described, with a 6 
colours staining cocktail including CD56, CD19, CD3, CD4, CD45RA, CD27 in order 
to separate NK-cells, B-cells, CD4+ and CD8+ T-cell subsets (Naïve, memory and 
effectors). Cell concentration achieved before sorting procedure was about 5 to 15 
x106 cells/ml, and addition of 1mM Na2EDTA to PBS resuspended cells was used to 
prevent cell clotting. Finally, PBMCs were purified with by high-throughput 
fluorescent-activated cell sorting with BD FACSAria II sorter. DNA extraction and 
STR analysis for chimerism assessment was made according to aforementioned 
procedure above. 
 
 
5.7 Statistical analysis 
 
Time-to-event outcomes were computed by using the Kaplan-Meier technique 
and were compared by using the two-tailed log-rank test. Overall survival (OS) was 
measured from day 0 to death from any cause or last known follow-up. Event-free 
survival (EFS) was defined as survival with sustained engraftment, with death and 
graft failure categorized as treatment failure. EFS was measured from day 0 to the 
first indicator of graft failure, death of any cause, or last known follow-up. Cumulative 
incidence of events (graft failure, GvHD) were estimated by using competing risk 
methods. Impact of specific variable on time-to-event outcomes was assessed by 
univariate and multivariate comparison analysis with Cox proportional hazards 
regression model. All data were censored as of the June 1, 2015.  
Differences in specific groups characteristics were analyzed using chi-square 
with Fisher's exact correction as appropriate. 
Statistical comparisons between biological variables were performed using the 
non-parametric Mann-Whitney U-test and Kruskal-Wasllis method. Differences were 
considered statistically significant when p values were less than 0.05. 
Statistical analysis was performed using SPSS 19.0 for Windows software 
(SPSS Inc.) and GraphPad Prism version 6.00 for Windows (La Jolla, California 
USA). 
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6. RESULTS 
 
 
6.1 Patient characteristics, engraftment and chimerism trend 
 
HSCT from a Matched Sibling donor (MSD) was performed in 12 (26.6%) 
patients, and in 33 (73.4%) from an Unrelated Donor (UD), 8 (24.2%) of whom 
received 2 Gy TBI for 9/10 mismatch. Graft source used was PBSC in 38 (84.5%) 
patients, and BM in 7 (15.5%). The median interval from diagnosis to HSCT was of 
5.4 months (Range 2,5 – 34,7). The median CD34+ cell dose given was of 6.55 
(Range 1.97 - 12.4)x106/Kg. Engraftment rate was excellent, with a median time to 
neutrophil recovery of 11 days (Range 10 - 22), and to platelet recovery of 12 days 
(range 9 - 61). Only one (2,2%) primary graft failure was recorded after transplant, 
with a second HSCT successfully performed as salvage treatment. No episodes of 
late onset graft failure/rejection were recorded in this cohort of patients (Table 5). 
Chimerism status data were sequentially available in 42 (93.3%) patients for 
unfractioned BM, CD3+ and CD15+ PB cells (respectively lymphoid and granulocytic 
chimerism). Pattern of persistently mixed lymphoid chimerism, as previously 
observed with FCC conditioning regimen, was confirmed in this cohort of patients; 
median level of CD3+ chimerism was respectively 52.7% (SE ±7.1%), 61.7 (SE 
±5.7%) and 81.8 (SE ±4.9%) at day +90, at +1 year and at +3 year after 
transplantation, even after CyA suspension. On the contrary, rapid and persistent full 
donor engraftment for PB granulocytic fraction and Unfractioned BM was promptly 
observed in all but one patient at day +90 onward. Very interestingly, higher level of 
CD3+ chimerism, with achievement of persistent full donor engraftment, both for 
lymphoid and granulocytic fraction, was observed in 8 patients (17.3%), 6 of them 
receiving TBI as part of their conditioning regimen (Fig. 7).  
 
 
 
6.2 GvHD, infections and autoimmunity 
 
Acute GvHD was observed in 6 (13.3%) patients, all of grade I-II. Chronic 
GvHD was observed in 5 (11.1%) patients, (3 mild, 1 moderate, 1 severe as per NIH 
scoring system), all with skin as the only site of involvement. Cumulative incidence of 
GvHD at 1 year was respectively of 16,2% (Fig.8). On uni- and multivariate analysis 
with Cox regression model, factors significantly predicting chronic gvhd were 1) 
previously diagnosed acute GVHD (p=0.035) and 2) CD3+ chimerism at 
day+100≥90% (p=0.006). GvHD contributed to the death of only one patient, where 
severe skin involvement was associated with occurrence of multiple thrombosis and 
septicemia.   
 EBV viremia was detectable in 20 (44.4%) patients, but for only two 
(4.4%) of them a specific treatment was needed: in one patient a proper diagnosis of 
post-transplant lymphoproliferative disorder (PTLD) was made, while in the other one 
therapy with rituximab was started only for excessive viral load, but in absence of 
signs of lymphoproliferative disease. CMV viremia was detected in 11 (24.2%) 
patients, but no one progressed to CMV disease due to pre-emptive therapy. 
Adenovirus viremia was observed in 3 (6.6%) patients. Invasive Fungal infections 
(IFI) were diagnosed in three (6.6%) patients, with fatal outcome for two of them. 
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 Seven cases (15.5%) of post-HSCT autoimmune disorders were 
recorded. Immune-mediated cytopenia were observed in 6 patients (13.3%) (2 
PRCA, 3 Haemolytic Anemia, 1 Autoimmune neutropenia), while in 1 (2.2%) an 
autoimmune hypothyroidism with detectable auto-antibodies was diagnosed. 
 
 
 
Table 5. post-HSCT clinical data          
Type of donor 
- Matched sibling (MSD) 
- Unrelated donor (UD) 
- 9/10 UD 
 
12 (26.6%) 
33 (73.4%) 
8 of 33 (24.2% of UD) 
Median time to transplant 
- MSD   
- UD  
 
 
5.4 months (Range 2.7 – 34.7) 
8.4 months (Range 2.1 – 178.9)  
 
Stem cell source 
- BM 
- PB 
7 (15.5%) 
38 (84.5%) 
Median Alemtuzumab dose 70 mg (Range 45 – 100) 
Median CD34+/Kg stem cell dose 6.55x10
6
 (Range 1.97 – 12.40) 
Median follow-up 31.4 months (Range 3 – 93) 
Median time to ANC > 0.5 x 10
9
/l 12 days (Range 10 – 22) 
Median time to platelets > 20 x 10
9
/l 12 days (Range 9 – 61) 
Primary graft failure 1 (2.2%) 
1 yr TRM 3 (6.6%) 
Acute GVHD: 
- Grade I/II 
- Grade III/IV 
6 (13.3%) 
- 6 of 6 (100%) 
- 0 of 6 
Chronic GVHD: 
- Mild 
- Moderate 
- Severe 
6 (13.3%) 
- 4 of 6 (66%) 
- 1 of 6 (17%) 
- 1 of 6 (17%) 
Documented viral infections: 
- Adenovirus 
- CMV 
- EBV 
34 (75.2%) 
- 3  (6.6%) 
- 11 (24.2%) 
- 20 (44.4%) 
Post-HSCT autoimmunity: 
- Immune cytopenia 
- Other 
 
7 (15.5%) 
- 6 (13.3%) 
- 1 (2.2%) 
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6.3 Survival analysis 
 
Overall survival and event-free survival were respectively of 93.1% and 90.7% 
at 1 years after transplant, without further decrease on prolonged follow-up (Fig.8). 
Three patients died after HSCT, accounting for an overall TRM rate at 1 year of 
6.6%. Cause of death were IFI for two of them, and multi-organ failure due to 
haemolytic anemia, septicemia and severe chronic GvHD in one of them.  
No significant impact of age, stem cell dose, stem cell source and type of 
donor was observed on Cox Univariate and Multivariate regression analysis, both for 
OS (Fig.9) and EFS (Fig.10) in this cohort of patients. 
 
  
 
 
Fig.7. Post-HSCT chimerism trend. Unf, unfractioned bone marrow; CD3, lymphoid fraction; 
CD15, granulocytic fraction.       
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              Fig.8. On top, General Overall and Event-free Surival.       
              Below, Cumulative Incidence of GvHD at 1 year.    
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              Fig.9.  No significant impact of Age, Donor, Stem cell source on OS. 
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               Fig.10. No significant impact of Age, Donor, Stem cell source on EFS. 
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6.4 Immune reconstitution dynamics after HSCT  
 
As expected from an Alemtuzumab based regimen, a profound depletion of all 
lymphocyte subsets is observed after transplant, with level of total lymphocytes 
remaining significantly lower (P<0,005) than normal still one year after 
transplantation. Sequential analysis of peripheral blood lymphocytes composition to 
monitor immune reconstitution showed that B-lymphocytes and NK-cells recovered 
first, with NK cells being the main lymphocyte population at day 90, accounting for a 
median level of 31,7% (p<0,005) and 28,4% (p<0,005) when compared to level of 
healthy age-matched volunteers. However  B-cell recovery was faster and more 
robust than NK-cells, with numbers of B-cells reaching the normal range at day 90 
along with T-cell after transplantation (Data shown in figure 11 and 12).  
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Fig. 11. Total lymphocytes, with B-cell, NK-cell, T-cell and T-cell 
frequencies (n° of cell/mmc) after FCC HSCT. As expected from an 
Alemtuzumab based regimen, cell counts remain extremely low, with 
only B-cells and gdT-cell recovering at almost normal level within 3 
months after transplant. Frequencies compared with healthy control 
group by Mann-Whitney U-test. 
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Fig. 12. Proportion (% of lymphocytes/mmc) of B-cell and NK-cell after FCC HSCT. 
Proportions of B and NK-cells remain significantly over normal within first six months after 
HSCT. Proportion compared with healthy control group by Mann-Whitney U-test. 
* = p<0,05 ; ** = p<0,005; *** = p <0,0005; NS = p>0,05 
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Fig. 13. Relative proportion (% of lymphocytes/mmc) of T-cell, B-cell and NK-cell after 
FCC HSCT. B-cell and NK cell remain the predominant lymphocyte type until one year 
after FCC HSCT, when proportion of T-cell tend to increase.  
 
 
 
 
CD3+ T-cells remained profoundly deficient after transplant, comprising only 
1.76% of total lymphocytes at day 30, and rising up to 43.8% by day 360, but still 
significantly below normal (66%, p=0.018) (Fig. 13).  
T-cell subset composition was investigated by analyzing expression of CD4+ 
and CD8+ surface antigen to discriminate between Helper and cytotoxic 
lymphocytes. Investigation of T-cell subsets was made by surface marker expression 
analysis of CD45RA, which expressed on naïve cells, and co-stimulatory molecule 
CD27, which is lost during antigen-induced differentiation to effector elements.  
Number of CD4+ T-cells and CD8+ T-cells remained significantly below 
normal within 1-year after HSCT, but in terms of recovery CD8+ were proportionally 
faster than CD4+ T-cells, producing as consequence a disruption with inversion of 
physiological CD4+/CD8+ T-cell ratio observed in peripheral blood as for healthy 
individuals (Figure 14). 
Cell numbers, expressed as n° of elements/mmc, within CD4+ and C8+ T-cell 
subsets remained profoundly deficient after HSCT. However some differences were 
present: composition of both CD4+ and CD8+ T-cell populations was relatively 
defective in naïve cells and memory cells, especially when compared to age–
matched healthy volunteers. On the other hand, number of terminally differentiated 
effector elements (Effectors, terminal effectors or total effectors) tended to recover 
within normality at 1-year after HSCT in the CD8+ T-cell fraction (data shown in fig.15 
and fig. 16). 
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Fig. 14. Relative recovery (% of lymphocytes/mmc) of CD4+ and CD8+ T-cells after FCC 
HSCT. Disruption of normal CD4+/CD8+ ratio observed in comparison with healthy 
individuals. 
 
 
 
 
 
When immune reconstitution of T-cell was analyzed in term of percentage of 
T-lymphocytes, within the CD4+ T-cells subset the proportion of Naïve cells 
increased constantly after HSCT, reaching a level at day 360 proportionate to healthy 
control group (p=0,131), and reconstituting an almost normal subset composition with 
Memory and Effectors at the same time-point after transplantation (Figure 17). 
Moreover, expression of surface markers associated with recent thymic 
egression (RTEs = CD31+ CD62L+ CD45RA+) that indicates renewed thympoiesis 
was evaluated within CD4+ T-cell Naïve cells. Patients aged less than 50 years 
showed more effective recovery of RTEs, indicating renewed thymopoiesis, and 
potential implementation of central tolerance after transplant (Figure 18).  
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Fig. 15. Total CD4+ lymphocytes (n° of cell/mmc), and relative subsets (Naïve, Memory and 
Effector cells) after FCC HSCT. Profund CD4+ cytopenia is present, with number remaining 
below normal one year after transplant. Frequencies compared with healthy control group 
by Mann-Whitney U-test. 
* = p<0,05 ; ** = p<0,005; *** = p <0,0005; NS = p>0,05 
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Fig. 16. Total CD8+ lymphocytes (n° of cell/mmc), and relative subsets (Naïve, Memory and 
Effector cells) after FCC HSCT. Even for CD8+ profund cytopenia is observed, but a relative 
recover of effector fraction in later timepoints is present. Frequencies compared with 
healthy control group by Mann-Whitney U-test. 
* = p<0,05 ; ** = p<0,005; *** = p <0,0005; NS = p>0,05 
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Fig. 17.  Relative recovery (% of lymphocytes/mmc) of CD4+ T-cells after FCC.  
CD4+ T-cells recover to a proportionally normal composition 1-year after HSCT. 
 
  
Fig. 18.  Recover of CD4+ recently thymic emigrant after FCC highligths presence of 
central tolerance in AA patients. 
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Composition of CD8+ T-cell subset population remained skewed toward 
effectors cells, with a relatively defective number of naïve cells across one year after 
transplant. As consequence, level of CD8+ Effectors T-cells proportion observed was 
higher than normal (57,2% of CD8 T cells compared to 9,3% for healthy individuals, 
p<0,005) highlighting a potential effect of antigenic stimulation on CD8+ T-cell 
reconstitution (Fig. 19). 
 
 
 
Fig. 19.  Relative recovery (% of lymphocytes/mmc) of CD8+ T-cells after FCC (See on top).  
CD8+ T-cells remain skewed due to augmented proportion CD8+ Effector T-cell, which 
persists at 1-year after HSCT (See below). 
* = p<0,05 ; ** = p<0,005; *** = p <0,0005; NS = p>0,05 
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6.5 Lymphocytes subsets chimerism analysis 
 
Given CD3+ persistent mixed chimerism status observed in this cohort after 
transplantation, T-cell subsets from five patients were isolated by fluorescence-
activated cell sorting, and chimerism status assessed specifically. This analysis 
revealed that mixed T-cell chimerism at day 360 was principally due to persistence of 
patient CD8+ T-cells, with notable contribution of the Effector subset. Follow-up 
analysis of three patients at >2 years after HSCT showed that the mixed chimerism 
profile within T-cell subsets remained stable across time (Figure 20).  
 
 
 
 
 
Fig. 20.  Lymphocyte subset chimerism status at 1-year after FCC HSCT. Proportion of donor 
and recipient cell remain significantly different within different subsets. 
 
 
 
A significant correlation was observed between lower donor T-cell chimerism 
at day 360 and CMV reactivation or EBV viremia early after HSCT (p=0.036), 
suggesting that antigen-driven expansion of virus-specific patient CD8 effector T cells 
may substantially contribute to persistent mixed T-cell chimerism (Figure 21).   
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Fig. 21.  Dot plot showing chimerism level (with median bars) according to 
Viral reactivation in FCC transplanted AA patients . 
 
 
However, analysis of PBMC from one HLA-A*02:01 CMV+ patient with HLA-
A*02:01-NLV-pentamer lead to show T-cell specific CMV reactivity did not show high 
frequencies of CD8 T cells specific for this single epitope (fig. 22). 
 
 
 
Fig. 22.  Experiment showing HLA-A*02:01-NLV-specific CD8+ T-cells . 
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6.6 Regulatory lymphocytes subsets after HSCT 
 
Sustained co-existence of donor and patient T cells and low rates of GVHD 
indicates conditions favoring mutual tolerance, therefore we looked for the potential 
role of cells with immunomodulatory properties after transplantation.  
As discussed above, B-cell recovery was robust and faster than NK- and T-
cells, achieving normal numbers in peripheral blood by day 100, with a B-cell/T-cell 
ratio within peripheral blood remaining significantly higher than normal, especially in 
the early post-transplant period. Moreover study of B-cell subset dynamics revealed 
early after HSCT a significantly increased proportion of cells with an immature 
transitional phenotype (CD24+ CD38+, CD27- IgMhigh IgDhigh 17.1% compared to 2.7% 
for healthy individuals, p=<0.005) that recently have been deemed to possess 
regulatory properties (Fig. 23). 
 
 
 
Fig. 23. On left, abnormal B/T-cell ratio after FCC HSCT. On right, dynamics of B-cell subsets. 
 
 
T1T2 B-lymphocytes have been showed100 to possess functional suppressive 
activities through expression of inhibiting cytokines, like IL-10 and TGF. Therefore 
ability to produce IL-10 was assessed in B-cells after in vitro stimulation with CD40L; 
an higher than normal proportion of IL10-producing B-cells was found in these 
patients (14.6% compared to 6.3% for healthy individuals, p=0.013), consistent with 
the known immunosuppressive activity of immature B-cells (Fig. 24).  
Furthermore, we looked for presence of regulatory CD4+ T-cells (CD4+ 
CD25high CD27+ FoxP3+), which normally suppress the activity of effector T-cells, and 
consequently, could have a beneficial role in creating a tolerant post-HSCT 
environment and in controlling GvHD. Enumeration of CD4+ CD25high Foxp3+ T 
cells showed that the numbers of these regulatory cells after transplantation 
remained lower than normal across all the post-transplant period, as expected by low 
T-cell number within these patients. However  proportions of regulatory T-cells within 
the CD4+ T-cell population remained normal (range 4.2-7.4% compared to 5.3% in 
healthy controls), suggesting a potential balanced effect of these cells towards 
effector T-cells compartment (Fig. 25). 
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Fig. 24. IL10+ B-cells after FCC HSCT. B10+ cells are presented as percentage of B-cells. Level are 
compared with healthy controls (HC).  
 
 
 
 
 
Fig. 25. T-regs reconstitution after-HSCT. On right, T-regs frequencies. On left, T-regs 
proportions. 
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7. DISCUSSION 
 
At current state, HSCT is only long-term curative option for patients affected 
by AA. Aims of allogeneic transplantation in this setting should be different from aims 
for treatment of other hematological conditions, like Acute Leukemia. As a matter of 
fact, AA remains an non-neoplastic disease for which stem cell transplantation 
should be used not only for gaining a complete hematological response, but actually 
for achieving a complete cure process trough preservation of patients long-term 
quality of life, including focusing on specific issues like reduced late toxicities (i.e. 
increased risk of cardiovascular disease or second cancers) and preservation of 
fertility in younger people. In this perspective, reduction of complication classically 
associated with HSCT in AA, like augmented incidence of graft rejection, and GvHD, 
especially chronic, remain an extremely compelling object of research. 
Addition of a T-cell lympho-depleting agent to conditioning in order to prevent 
GvHD, and adoption of reduce intensity conditioning (RIC) chemotherapy regimen for 
older patient, in order to reduce transplant-related toxicities trough a reduced dose of 
chemotherapy delivered, have been unanimously recognized as successful 
achievement in this direction. 
Several evidences suggested that FCC conditioning regimen, combining the 
extremely lympho-depleting activity of monoclonal anti-CD52 antibody Alemtuzumab 
with a RIC chemotherapy including FLU and Cy, is able to satisfy all the above 
conditions and guarantee low rates of long-term post-transplant side effects (In 
competition with other conditioning regimen aforementioned in the introduction like 
Cy200-ATG and FCA). Major concerns about wide spreading of FCC in transplant 
practice for AA persist due to relatively short follow-up information available in the 
experience reported in literature, and absence of immunological data supporting 
validity of this regimen from a biological point of view. Our study provides good 
answers to both these two kind of extremely important questions. 
First of all, a consistent and homogeneously treated number of patients (N = 
45) is available in this study for survival analysis with a median follow-up time 
superior to 32 months, which is quite exceptional considering rarity of the disease. 
Excellent survival rate are confirmed (See fig. 8,9,10), absolutely competitive to the 
average reported in medical literature, and a reduced incidence of both early and late 
complication is observed, especially graft failure, which show an incredibly low rate in 
this cohort (2.2%; see table 5), and chronic cGvHD, which appear limited in terms of 
number of patient affected, grade severity and of organ damaged (Only one patient 
with severe cGvHD and exclusive skin involvement; see table 5). These features are 
even more interesting if we consider that PBSC is the most commonly used source of 
HSC, and MUD is most frequently used type of donor. As reported in the introduction, 
both these factor should be associated with higher incidence of GvHD and graft 
failure, with a direct reflection on survival. However all these problems seem 
apparently resolved in our FCC cohort. More interestingly, a consistent part of 
patients remain persistently mixed chimeric, even more than one year after 
transplant, when cyclosporine is completly suspended (Fig. 7). These feature is 
extremely interesting if we considered that a mixed chimerims status in AA is a 
consistent risk factor for graft rejection, in particular when a dropping tendency is 
observed. Nevertheless, this tendency is not observed in our patients, where a 
pacific co-existence between donor and recipient cells seems to be established, 
which actually suggest achievement of a tolerant immune environment. These data 
are concordant with the fact that a significant risk for cGVHD in our cohort is the rapid 
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establishment of full donor chimerism status at day +90, suggesting a not well 
counterbalanced immune activity of donor cells in these patients. 
Our immunological data give some intel about all these peculiar clinical 
aspects occurring after FCC transplant. Firstly, lympho-depleting activity of this 
Alemtuzumab-based regimen is so strong that lymphocyte counts do not show 
complete recover even one year after HSCT. Particularly, this condition affects the T-
cell compartment, which a huge amount of data available in literature indicate as 
responsible for triggering and perpetuating post-HSCT immune phenomena as graft 
rejection or GvHD. However in our patients T-cell counts tend to recover across time, 
with phenomena indicative of potential reducation during recovery. 
CD4+ T-cell compartment, for example, shows a continuous improvement in 
count of Naïve CD4+ T-cells across time. Most of these cell express markers of 
recently thymic emigration in younger patients, indicating that thymus is active after 
transplant, and probably has a role in reeducating lymphocyte not to trigger immune 
reaction against host antigens, how actually GvHD is. On the contrary, CD8+ T-cell 
compartment do not show generation of big counts of Naïve CD8+ T-cells, while an 
augmented proportion of CD8+ Effector cells, which currently constitute the armed 
branch of the immune system, is predominant. This phenomena is so pronounced 
that physiological CD4/CD8 ratio is altered. This condition remain quite unusual, if we 
consider that CD8+ Effectors expansion should be avoidable in AA, given the 
immune pathogenesis of the disease (see Introduction). Nevertheless, graft failure, 
which we can actually consider disease relapse, is not present with an augmented 
rate in our patients (Actually is the opposite). A potential explanation is that only few 
CD8+ clones with a stereotypical TCR can expand after FCC HSCT, and that these 
cell are not able to promote or perpetuate GvHD. Viral infection occur at an high rate 
in our cohort, even if remain clinical irrelevant due to intense clinical monitoring (See 
table 5). Lower chimerism level in patients with active viral reactivations (see fig. 21), 
and specifically high level of recipient cell in CD8+ T-cell fraction (see fig. 20), 
suggest that the higher incidence of viral infection caused by Alemtuzumab are 
probably able to expand TCR-restricted cells of recipient origin; these cells are not 
able to attack the HSC due to their viral specificity, nor to promulgate GvHD due to 
their autologous nature. Finally presence of regulatory element (T-regs, and IL10+ B-
regs) may promote the forced coexistence between donor and recipient cell 
(persistent mixed chimerism status, eventually started by viral stimulation), and may 
facilitate the persistence of a suppressive/permissive post-HSCT immune 
environment. Of note, even if this hypothesis was not confirmed when we looked for 
NLV-CMV-peptide-specific CD8+ T-cells, it was a single experiment, while is 
probable that in these patients different epitopes, from different peptides, and 
probably even form different viruses, need to be explored, before drawing any 
conclusion, given the elevate number of viral infections observed in clinic (see table 
5). 
Finally our study confirm excellent clinical outcome for patients receiving 
HSCT for AA with FCC regimen, and for first time provides critical hints on efficacy on 
this treatment approaching the dynamics of immune reconstitution after 
transplantation. Advancement of knowledge in this filed would eventually provide new 
understandings in clinical management of these patients, gaining higher rates of 
successful cure for this rare and difficult disease. 
 
 
 
49 
 
8. REFERENCES 
 
1. Bennett JM, Orazi A. Diagnostic criteria to distinguish hypocellular acute 
myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic 
anemia: recommendations for a standardized approach. 
Haematologica 2009; 94: 264–268. 
2. Killick S, Brown N, Cavenagh J et al. Guidelines for the diagnosis and 
management of adult aplastic anemia. (2016); BJHaem 172:187-207. 
3. Rovó A, Tichelli A and Dufour C. Diagnosis of acquired aplastic anemia.  
Bone Marrow Transplantation (2013) 48, 162–167. 
4. Heimpel, H. Epidemiology and aetiology of aplastic anaemia. In: Aplastic 
Anaemia: Pathophysiology and Treatment (ed. by H. Schrezenmeier & A. 
Bacigalupo), pp. 97–116. (2000)  
Cambridge University Press, Cambridge, UK. 
5. Montané E, Ibanez L, Vidal X et al. (2008) Epidemiology of aplastic anaemia: 
a prospective multicenter study. (2008) Haematologica 93:518–23. 
6. Kaufman DW, Kelly JP, Levy M et al.  The drug etiology of agranulocytosis 
and aplastic anemia (1991); (Oxford University Press, New York).  
7. Mary JY, Baumelou M, Guiguet M and the French Cooperative Group for 
Epidemiological Study of Aplastic Anemia. Epidemiology of aplastic anemia in 
France: a prospective multi-centric study. (1990) Blood. 75:1646–53. 
8. Cartwright RA, McKinney PA, Williams L et al. Aplastic anaemia incidence in 
parts of the United Kingdom in 1985. (1988); Leuk Res. 12:459–63. 
9. Clausen N,   Kreuger A, Salmi T et al. Severe aplastic anaemia in the Nordic 
countries: a population based study of incidence, presentation, course, and 
outcome. (1996) Arch Dis Child. 74:319–22. 
10. Maluf EM, Pasquini R, Eluf JN et al.  Aplastic anemia in Brazil: incidence and 
risk factors. (2002) Am J Hematol. 71:268–74.  
11. Issaragrisil S, Kaufman DW, Anderson T et al. The epidemiology of aplastic 
anemia in Thailand. (2006) Blood. 107:1299–307.  
12. Yang C, Zhang X.  Incidence survey of aplastic anemia in China. (1991) Chin 
Med Sci. J6:203–7. 
13. Qing L, Luoping Z, Guilan L et al. Hematotoxicity in Workers Exposed to Low 
Levels of Benzene (2004) Science Vol. 306, Issue 5702, pp. 1774-1776. 
14. Qing L, Luoping Z, Min S et al. Polymorphisms in Cytokine and Cellular 
Adhesion Molecule Genes and Susceptibility to Hematotoxicity among 
Workers Exposed to Benzene. (2005) Cancer Res 65:9574–81. 
15. Young NS, Alter BP and Young NS, (1994) in Aplastic Anemia, Acquired and 
Inherited, Drugs and chemicals. Eds Young NS, Alter BP. (W.B. 
Saunders, Philadelphia), pp 100–32. 
16. Mishra B, Malhotra P, Ratho RK et al. Human Parvovirus B19 in patients with 
aplastic anemia. (2005) Am J Hematol. 79:166–167. 
17. Pardi DS, Romero Y, Mertz LE, Douglas DD. Hepatitis-associated aplastic 
anemia and acute parvovirus B19 infection: a report of two cases and a review 
of the literature. (1998) Am J Gastroenterol. 93: 468–70. 
18. Adachi Y, Yasui H, Yuasa H, Ishi Y, Imai K, Kato Y. Hepatitis B virus-
associated aplastic anemia followed by myelodysplastic syndrome. (2002) Am 
J Med. 112: 330–2.  
19. Byrnes JJ, Banks AT, Piatack M Jr, Kim JP. Hepatitis G-associated aplastic 
anaemia. (1996) Lancet. 348: 472.  
50 
 
20. Lau YL, Srivastava G, Lee CW et al. Epstein-Barr virus associated aplastic 
anaemia and hepatitis. (1994) J Paediatr Child Health. 30: 74–6. 
21. Imai T, Itoh S, Okada H et al. Aplastic anemia following hepatitis associated 
with echovirus 3. (2002) Pediatr Int. 44: 522–4. 
22. Pagliuca S, Gérard L, Kulasekararaj A et al. Characteristics and outcomes of 
aplastic anemia in HIV patients: a brief report from the severe aplastic anemia 
working party of the EBMT. Bone Marrow Transplantation, 2016. 51: 313–315. 
23. Brown KE, Tisdale J, Barrett AJ et al. Hepatitis-associated aplastic anemia. 
(1997) N Engl J Med. 336: 1059–64. 
24. R. Gonzalez-Casas, L. Garcia-Buey, Jones EA et al. Systematic review: 
hepatitis-associated aplastic anaemia – a syndrome associated with abnormal 
immunological function.(2009) Aliment Pharmacol Ther. 30: 436–443. 
25. NS Young, RT Calado, P Scheinberg. Current concepts in the 
pathophysiology and treatment of aplastic anemia. (2006) Blood, 108(8) - Am 
Soc Hematology. 
26. Young NS. Hematopoietic cell destruction by immune mechanisms in aquired 
aplastic anemia. Semin Hematol. 2000;37: 3-14. 
27. Sloand EM, Kim S, Maciejewski JP, et al. Intracellular interferon-γ in 
circulating and marrow T cells detected by flow cytometry and the response to 
imunosuppressive therapy in patients with aplastic anemia. Blood. 2002;100: 
1185-1191. 
28. Risitano AM, Maciejewski JP, Green S, et al. In vivo dominant immune 
responses in aplastic anaemia: molecular tracking of putatively pathogenetic 
T-cell clones by TCR beta-CDR3 sequencing. Lancet. 2004;364: 355-364. 
29. Selleri C, Maciejewski JP, Sato T, Young NS. Interferon-γ constitutively 
expressed in the stromal microenviroment of human marrow cultures mediates 
potent hematopoietic inhibition. Blood. 1996; 87: 4149-4157. 
30. Maciejewski JP, Selleri C, Anderson S, Young NS. Fas antigen expression on 
CD34+ human marrow cells is induced by interferon-gamma and tumor 
necrosis factor-alpha and potentiates cytokine-mediated hematopoietic 
suppression in vitro. Blood. 1995;85: 3183-3190. 
31. Fischer U, Ruckert C, Hubner B et al. CD34+ gene expression profiling of 
individual children with very severe aplastic anemia indicates a pathogenic 
role of integrin receptors and the proapoptotic death ligand TRAIL. 
Haematologica. 2012 Sep;97(9):1304-11. 
32. Lin FC, Karwan M, Saleh B et al. IFN-γ causes aplastic anemia by altering 
hematopoietic stem/progenitor cell composition and disrupting lineage 
differentiation. Blood. 2014 Dec 11;124(25):3699-708. 
33. Sato T, Selleri C, et al. Expression and modulation of cellular receptors for 
interferon-gamma, tumour necrosis factor, and Fas on human bone marrow 
CD34+ cells. Br J Haematol 1997; 97: 356-365. 
34. Maciejewski JP, Selleri C et al. Increased expression of Fas antigen on bone 
marrow CD34+ cells of patients with aplastic anaemia. Br J Haematol 1995; 
91: 245-252. 
35. Hirano N, Butler MO et al. Autoantibodies frequently detected in patients with 
aplastic anemia. Blood. 2003;102: 4567-4575. 
36. Feng X, Chuhjo T, Sugimori C, et al. Diazepam-binding inhibitor-related 
protein 1: a candidate autoantigen in acquired aplastic anemia patients 
harboring a minor populatoin of paroxysmal nocturnal hemoglobinuria-type 
cells. Blood. 2004; 104: 2425-2431. 
51 
 
37. Gargiulo L, Papaioannou M, Sica M et al. Glycosylphosphatidylinositol-
specific, CD1d-restricted T cells in paroxysmal nocturnal hemoglobinuria. 
Blood. 2013 Apr 4;121(14):2753-61. 
38. Maciejewski JP, Selleri C, Sato T et al. A severe and consistent deficit in 
marrow and circulating primitive hematopoietic cells (long-term culture-
initiating cells) in acquired AA. Blood 1996; 88: 1983-1991. 
39. Bacigalupo A, Piaggio G et al. Collection of peripheral blood hematopoietic 
progenitors (PBHP) from patients with severe aplastic anemia (SAA) after 
prolonged administration of granulocyte colony-stimulating factor. Blood 1993; 
82: 1410-1414. 
40. Scopes J, Bagnara M et al. Haemopoietic progenitor cells are reduced in 
aplastic anaemia. Br J Haematol 1994; 86: 427-430. 
41. Manz CY, Nissen C et al. Deficiency of CD34+ c-kit+ and CD34+38- 
hematopoietic precursors in aplastic anemia after immunosuppressive 
treatment. Am J Hematol 1996; 52: 264-274. 
42. Schrezenmeier H, Jenal M et al. Quantitative analysis of cobblestone area-
forming cells in bone marrow of patients with aplastic anemia by limiting 
dilution assay. Blood 1996; 88: 4474-4480. 
43. Sutherland HJ, Eaves CJ et al. Characterization and partial purification of 
human marrow cells capable of initiating long-term hematopoiesis in vitro. 
Blood 1989; 74: 1563-1570. 
44. Pettengell R, Luft T et al. Direct comparison by limiting dilution analysis of 
long-term culture-initiating cells in human bone marrow, umbilical cord blood, 
and blood stem cells. Blood 1994; 84: 9.  
45. Maciejewski JP, Kim S, Sloand E, Selleri C, Young NS. Sustained long-term 
hematologic recovery despite a marked quantitative defect in the stem cell 
compartment of patients with aplastic anemia after immunosuppressive 
therapy. Am J Hematol 2000; 65: 123-131. 3653-3659. 
46. Podesta M, Piaggio G et al. The assessment of the hematopoietic reservoir 
after immunosuppressive therapy or bone marrow transplantation in severe 
aplastic anemia. Blood 1998; 91: 1959-1965. 
47. Rizzo S, Scopes J et al. Stem cell defect in aplastic anemia: reduced long 
term culture-initiating cells (LTC-IC) in CD34+ cells isolated from aplastic 
anemia patient bone marrow. Hematol J 2002; 3: 230-236. 
48. Marsh JC, Chang J et al. In vitro assessment of marrow 'stem cell' and stromal 
cell function in aplastic anaemia. Br J Haematol 1991; 78: 258-267. 
49. Novitzky N and Jacobs P. Immunosuppressive therapy in bone marrow 
aplasia: the stroma functions normally to support hematopoiesis. Exp Hematol 
1995; 23:1472-1477. 
50. Novitzky N and Jacobs P. Marrow stem cell and stroma cell function in aplastic 
anaemia. Br J Haematol 1991; 79: 531-533. 
51. Socie G, Rosenfeld S, Frickhofen N, Gluckman E, Tichelli A. Late clonal 
diseases of treated aplastic anemia. Semin Hematol 2000; 37: 91–101. 
52. Tichelli A, Gratwohl A, Nissen C, Speck B. Late clonal complications in severe 
aplastic anemia. Leuk Lymphoma 1994; 12: 167–175.  
53. Young NS, Maciejewski JP et al. The relationship of aplastic anemia and PNH. 
Int. J Hematol 2002; 76(Suppl 2): 168–172. 
54. Pu JJ, Mukhina G et al. Natural history of paroxysmal nocturnal 
hemoglobinuria clones in patients presenting as aplastic anemia. Eur J 
Haematol 2011; 87: 37–45. 
52 
 
55. Gupta V, Brooker C, Tooze JA, Yi QL, Sage D, Turner D et al. Clinical 
relevance of cytogenetic abnormalities at diagnosis of acquired aplastic 
anaemia in adults. Br J Haematol 2006; 134: 95–99. 
56. Calado RT, Cooper JN, et al. Short telomeres result in chromosomal instability 
in hematopoietic cells and precede malignant evolution in human aplastic 
anemia. Leukemia 2012; 26: 700–707. 
57. Cagatay Günes and K. Lenhard Rudolph. The Role of Telomeres in Stem 
Cells and Cancer. 2013. Cell (152)2. 
58. Bogdan Dumitriu, Xingmin Feng et al. Telomere attrition and candidate gene 
mutations preceding monosomy 7 in aplastic anemia. 2015. Blood: 125 (4). 
59. Calado RT and Young NS. Telomere disease. N Engl J Med 2009; 361:2353-
2365. 
60. Fogarty PF, Yamaguchi H, Wiestner A et al. Late presentation of dyskeratosis 
congenita as apparently acquired aplastic anaemia due to mutations in 
telomerase RNA. Lancet 362:1628–1630. 
61. Kulasekararaj A, Jiang j et al. Somatic mutations identify a subgroup of 
aplastic anemia patients who progress to myelodysplastic syndrome. 2014; 
Blood: 124 (17). 
62. Yoshizato T, Dumitriu B et al. Somatic Mutations and Clonal Hematopoiesis in 
Aplastic Anemia. N Engl J Med 2015; 373:35-47. 
63. Jaiswal S, Fontanilla P et al. Age-Related Clonal Hematopoiesis Associated 
with Adverse Outcomes. N Engl J Med 2014; 371:2488-2498. 
64. Genovese G, Kähler KA et al. Clonal Hematopoiesis and Blood-Cancer Risk 
Inferred from Blood DNA Sequence. N Engl J Med 2014; 371:2477-2487. 
65. Risitano AM. Immunosuppressive therapies in the management of immune‐
mediated marrow failures in adults: where we stand and where we are going. 
2011. British journal of haematology. 152:2. 
66. Frickhofen N, Kaltwasser JP et al. Treatment of aplastic anemia with 
antilymphocyte globulin and methylprednisolone with or without cyclosporine. 
The German Aplastic Anemia Study Group. New England Journal of Medicine, 
324, 1297–1304. 
67. Locasciulli A, Oneto R et al. Severe Aplastic Anemia Working Party of the 
European Blood and Marrow Transplant Group. (2007) Outcome of patients 
with acquired aplastic anemia given first line bone marrow transplantation or 
immunosuppressive treatment in the last decade: a report from the European 
Group for Blood and Marrow Transplantation (EBMT). Haematologica (92) 11–
18. 
68. Feng X,  Kajigaya S et al. Rabbit ATG but not horse ATG promotes expansion 
of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. Blood. 2008: 
111 (7). 
69. Scheinberg P, Nunez O et al. Horse versus rabbit antithymocyte globulin in 
acquired aplastic anemia. N Engl J Med. 2011 Aug 4;365(5):430-8.  
70. Marsh JC, Bacigalupo A, Schrezenmeier H, et al. Prospective study of rabbit 
antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT 
Severe Aplastic Anaemia Working Party. Blood 2012;119(23):5391-5396. 
71. Teramura M, Kimura A et al. Treatment of severe aplastic anemia with 
antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a 
multicenter randomized study in Japan. Blood, 110, 1756–1761. 
53 
 
72. Scheinberg P, Nunez O et al. Treatment of severe aplastic anaemia with 
combined immunosuppression: antithymocyte globulin, ciclosporin and 
mycophenolate mofetil. British Journal of Haematology, 133, 606–611. 
73. Scheinberg P, Wu CO, Nunez O et al. Treatment of severe aplastic anemia 
with a combination of horse antithymocyte globulin and cyclosporine, with or 
without sirolimus: a prospective randomized study. Haematologica, 94, 348–
354. 
74. Brodsky RA, Chen AR et al. High-dose cyclophosphamide for severe aplastic 
anemia: long-term follow-up. (2010). Blood, 115, 2136–2141. 
75. Scheinberg P, Townsley D, et al. Moderate-dose cyclophosphamide for 
severe aplastic anemia has significant toxicity and does not prevent relapse 
and clonal evolution. Blood. 2014; 124 (18):2820-2823. 
76. Risitano AM, Selleri C, Serio B et al. Alemtuzumab is safe and effective as 
immunosuppressive treatment for aplastic anaemia and single-lineage marrow 
failure: a pilot study and a survey from the EBMT WPSAA. British Journal of 
Haematology, 148, 791–796. 
77. Storb R, Leisenring W, Anasetti C, et al. Long-term follow-up of allogeneic 
marrow transplants in patients with aplastic anemia conditioned by 
cyclophosphamide combined with antithymocyte globulin. Blood 
1997;89:3890–1. 
78. Aljurf M, Zahrani HA et al. Standard treatment of acquires severe aplastic 
anemia, in adult patients 18-40 years old, with an HLA identical sibling Bone 
Marrow Transplant 2013;48:178–9. 
79. Bacigalupo A, Brand R, Oneto R, et al. Treatment of acquired severe aplastic 
anemia: bone marrow transplantation compared with immunosuppressive 
therapy - The European Group for Blood and Marrow Transplantation 
Experience. Semin Hematol 2000;37:69–80. 
80. Champlin RE, Perez WS, Passweg JR, et al. Bone marrow transplantation for 
severe aplastic anemia: a randomized controlled study of conditioning 
regimens. Blood 2007;109:4582–5. 
81. Bacigalupo A, Socie´ G, Schrezenmeier H et al for WPSAA-EBMT. Bone 
marrow versus peripheral blood as the stem cell source for sibling transplants 
in acquired aplastic anemia: survival advantage for bone marrow in all age 
groups. Haematologica 2012;97(8):1142–8. 
82. Marsh JC, Pearce RM, Koh MB et al, British Society for Blood and Marrow 
Transplantation Clinical Trials Committee. Retrospective study of 
alemtuzumab vs ATG-based conditioning without irradiation for unrelated and 
matched sibling donor transplants in acquired severe aplastic anemia: a study 
from the British Society for Blood and Marrow Transplantation. Bone Marrow 
Transplant 2014;49(1): 42–8.  
83. Novitzky N, Thomas V et al. Reduced-intensity conditioning for severe aplasia 
using fludarabine and CY followed by infusion of ex vivo T-cell-depleted grafts 
leads to excellent engraftment and absence of GVHD. Bone Marrow 
Transplant. 2009 May;43(10):779-85. 
84. Gupta V, Eapen M, et al. Impact of age on outcomes after bone marrow 
transplantation for acquired aplastic anemia using HLA-matched sibling 
donors. Haematologica 2010;95(12):2119–25. 
85. Al-Zahrani H, Nassar A, Al-Mohareb F, et al. Fludarabine-based conditioning 
chemotherapy for allogeneic hematopoietic stem cell transplantation in 
54 
 
acquired severe aplastic anemia. Biol Blood Marrow Transplant 
2011;17(5):717–22. 
86. Maury S, Bacigalupo A et al. Improved outcome of patients older than 30 
years receiving HLA-identical sibling hematopoietic stem cell transplantation 
for severe acquired aplastic anemia using fludarabine-based conditioning: a 
comparison with conventional conditioning regimen. Haematologica 
2009;94(9):1312–5. 
87. Bacigalupo A et al. Bone marrow transplantation for Aplastic Anemia. Hematol 
Oncol Clin N Am, 2014 (10). 
88. Marsh JC, Gupta V et al. Alemtuzumab with fludarabine and 
cyclophosphamide reduces chronic graft-versus-host disease after allogeneic 
stem cell transplantation for acquired aplastic anemia. Blood. 2011 Aug 
25;118(8):2351-7. 
89. Schrezenmeier H, Passweg JR et al. Worse outcome and more chronic GVHD 
with peripheral blood progenitor cells than bone marrow in HLA-matched 
sibling donor transplants for young patients with severe acquired aplastic 
anemia: a report from the European Group for Blood and Marrow 
Transplantation and the Center for International Blood and Marrow Transplant 
Research. Blood 2007;110(4):1397–400. 
90. Bacigalupo A, Socie´ G, Schrezenmeier H, et al. Bone marrow versus 
peripheral blood as the stem cell source for sibling transplants in acquired 
aplastic anemia: survival advantage for bone marrow in all age groups. 
Haematologica 2012;97(8):1142–8. 
91. Chu R, Brazauskas R, Kan F, et al. Comparison of outcomes after 
transplantation of G-CSF-stimulated bone marrow grafts versus bone marrow 
or peripheral blood grafts from HLA-matched sibling donors for patients with 
severe aplastic anemia. Biol Blood Marrow Transplant 2011;17(7):1018–24. 
92. Socie G, Lawler M, Gluckman E, et al. Studies on hemopoietic chimerism 
following allogeneic bone marrow transplantation in the molecular biology era. 
Leuk Res 1995;19(8):497–504. 
93. Lawler M, McCann SR et al. Serial chimerism analyses indicate that mixed 
haemopoietic chimerism influences the probability of graft rejection and 
disease recurrence following allogeneic stem cell transplantation (SCT) for 
severe aplastic anaemia (SAA): indication for routine assessment of 
chimerism post SCT for SAA. Br J Haematol 2009;144:933–45. 
94. Maury S, Balere-Appert ML, Chir Z, et al. Unrelated stem cell transplantation 
for severe acquired aplastic anemia: improved outcome in the era of 
highresolution HLA matching between donor and recipient. Haematologica 
2007; 92:589–96. 
95. Deeg HJ, Amylon ID, Harris RE, et al. Marrow transplants from unrelated 
donors for patients with aplastic anemia: minimum effective dose of total body 
irradiation. Biol Blood Marrow Transplant 2001;7:208–15. 
96. Bacigalupo A, Socie´ G et al. Fludarabine, cyclophosphamide, antithymocyte 
globulin, with or without low dose total body irradiation, for alternative donor 
transplants, in acquired severe aplastic anemia: a retrospective study from the 
EBMT-SAA working party. Haematologica 2010; 95(6):976–82. 
97. Eapen M, Le Rademacher J, Antin JH, et al. Effect of stem cell source on 
outcomes after unrelated donor transplantation in severe aplastic anemia. 
Blood. 2011;118(9):2618–21. 
55 
 
98. Peffault de Latour R, Purtill D et al. Influence of nucleated cell dose on overall 
survival of unrelated cord blood transplantation for patients with severe AA. 
Study by EUROCORD and the aplastic anemia working party of the European 
group for blood and marrow transplantation. Biol Blood Marrow Transplant 
2011;17(1):78-85. 
99. Ciceri F, Lupo-Stanghellini MT et al. Haplo-identical transplantation in patients 
with acquired aplastic anemia. Bone Marrow Transplant 2013;48(2):183-5. 
100. Khoder A, Sarvaria A, et al. Regulatory B cells are enriched within the 
IgM memory and transitional subsets in healthy donors but are deficient in 
chronic GVHD. Blood. 2014;124(13):2034-45. 
 
 
 
 
 
 
9. AKNOWLEDGEMENTS 
 
The Author thank Prof. Judith C. Marsh and dr. Linda Barber (King’s College 
Hospital and King’s College University, London, United Kingdom) for their 
outstanding mentorship in the field of Aplastic Anemia and post-transplant 
immunology, and for their contribution and suggestions in the production of these 
data. 
 
 
 
 
 
10. PUBLICATIONS IN EXTENSO  
 
 
PhD Period  
 
1. Grimaldi F, Ghandi S, Risitano AM. Epidemiology of acquired bone 
marrow failure syndrome – Book chapter. On the behalf of SAAWP-
EBMT, 2016. Publication in press. 
 
2. Risitano AM, Marotta S, Calzone R, Grimaldi F, Zatterale A; all RIAF 
Contributors. Twenty years of the Italian Fanconi Anemia Registry: 
where we stand and what remains to be learned. Haematologica. 2016 
Mar;101(3):319-2. 
 
3. Clay J, Kulasekararaj AG, Potter V, Grimaldi F, McLornan D, Raj K, de 
Lavallade H, Kenyon M, Pagliuca A, Mufti GJ, Marsh JC. 
Nonmyeloablative peripheral blood haploidentical stem cell 
transplantation for refractory severe aplastic anemia. Biol Blood Marrow 
Transplant. 2014 Nov;20(11):1711-6. 
56 
 
 
 
 
 
Intership period (Pre-PhD) 
 
1. Picardi M, Zeppa P, Ciancia G, Pettinato G, Grimaldi F, Fabbricini R, Mainolfi 
C, Pane F. Efficacy and safety of rituximab treatment in patients with 
progressive transformation of germinal centers after Hodgkin lymphoma in 
complete remission post-induction chemotherapy and radiotherapy. Leuk 
Lymphoma. 2011 Nov;52(11):2082-9. 
 
2. Cella L, Conson M, Caterino M, De Rosa N, Liuzzi R, Picardi M, Grimaldi F, 
Solla R, Farella A, Salvatore M, Pacelli R. Thyroid V30 predicts radiation-
induced hypothyroidism in patients treated with sequential chemo-
radiotherapy for Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2012 Apr 
1;82(5):1802-8. 
 
3. Picardi M, Soricelli A, Grimaldi F, Nicolai E, Gallamini A, Pane F. Fused FDG-
PET/contrast-enhanced CT detects occult subdiaphragmatic involvement of 
Hodgkin's lymphoma thereby identifying patients requiring six cycles of 
anthracycline-containing chemotherapy and consolidation radiation of spleen. 
Ann Oncol. 2011 Mar;22(3):671-80. 
 
4. Rinaldi CR, Rinaldi P, Gemei M, Grimaldi F, Battipaglia G, Del Vecchio L, 
Martino B, Specchia G, Candoni A, Gugliotta L, Vannucchi AM, Barbui T, 
Pane F. JAK2V617F mutation persists in blasts and mature cells of 
transformed JAK2V617F-positive-myeloproliferative neoplasia: a European 
Leukemia Net (ENL) study. Am J Hematol. 2010 May;85(5):383-6. 
 
5. Zeppa P, Vigliar E, Cozzolino I, Troncone G, Picardi M, De Renzo A, Grimaldi 
F, Pane F, Vetrani A, Palombini L. Fine needle aspiration cytology and flow 
cytometry immunophenotyping of non-Hodgkin lymphoma: can we do better? 
Cytopathology. 2010 Oct;21(5):300-10. 
 
6. Picardi M, Soricelli A, Pane F, Zeppa P, Nicolai E, De Laurentiis M, Grimaldi 
F, Rotoli B. Contrast-enhanced harmonic compound US of the spleen to 
increase staging accuracy in patients with Hodgkin lymphoma: a prospective 
study. Radiology. 2009 May;251(2):574-82. 
 
7. Camera A, Rinaldi CR, Palmieri S, Cantore N, Mele G, Mettivier V, Miraglia E, 
Mastrullo L, Grimaldi F, Luciano L, Guerriero A, Rotoli B, Ferrara F. 
Sequential continuous infusion of fludarabine and cytarabine associated with 
liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed 
adult acute myeloid leukemia patients.  Ann Hematol. 2009 Feb;88(2):151-8. 
haematologica | 2016; 101(3) 319
Received: July 7, 2015. 
Accepted: November 27, 2015.
Pre-published: December 3, 2015.
©2016 Ferrata Storti Foundation
Check the online version for the most updated
information on this article, online supplements,
and information on authorship & disclosures:
www.haematologica.org/content/101/3/319
Material published in Haematologica is cov-
ered by copyright. All rights reserved to Ferrata
Storti Foundation. Copies of articles are
allowed for personal or internal use. A permis-
sion in writing by the publisher is required for
any other use.
Correspondence: 
azatt@tin.it
Ferrata Storti
Foundation
EUROPEAN
HEMATOLOGY
ASSOCIATION
Haematologica 2016
Volume 101(3):319-327
ARTICLEBone Marrow Failure
doi:10.3324/haematol.2015.133520
The natural history of Fanconi anemia remains hard to establishbecause of its rarity and its heterogeneous clinical presentation; since1994, the Italian Fanconi Anemia Registry has collected clinical, epi-
demiological and genetic data of Italian Fanconi Anemia patients. This reg-
istry includes 180 patients with a confirmed diagnosis of Fanconi anemia
who have either been enrolled prospectively, at diagnosis, or later on. After
enrollment, follow-up data were periodically collected to assess the clinical
course, possible complications and long-term survival; the median follow up
was 15.6 years. The main goal of the study was to describe the natural his-
tory of Fanconi anemia, focusing on the following variables: family history,
disease presentation, development of hematological manifestations, devel-
opment of malignancies, occurrence of hematopoietic stem cell transplanta-
tion and survival. Typical morphological and/or hematological abnormalities
and/or growth retardation were the most common manifestations at diagno-
sis; the majority of patients (77%) exhibited hematological abnormalities at
the initial presentation, and almost all (96%) eventually developed hemato-
logical manifestations. More than half of the patients (57%) underwent a
bone-marrow transplant. The occurrence of cancer was quite rare at diagno-
sis, whereas the cumulative incidence of malignancies at 10, 20 and 30 years
was 5%, 8% and 22%, respectively, for hematological cancers and 1%, 15%
and 32%, respectively, for solid tumors. Overall survival at 10, 20 and 30
years were 88%, 56% and 37%, respectively; the main causes of death were
cancer, complications of the hematological presentation and complications of
transplantation. These data clearly confirm the detrimental outcome of
Fanconi anemia, with no major improvement in the past decades.
Twenty years of the Italian Fanconi Anemia
Registry: where we stand and what remains 
to be learned
Antonio M. Risitano,1 Serena Marotta,1 Rita Calzone,2 Francesco Grimaldi,1
and Adriana Zatterale,2* on behalf of all RIAF Contributors
1Hematology, Department of Clinical Medicine and Surgery, “Federico II” University;
2Genetics Unit, ASL Napoli 1, Naples, Italy
ABSTRACT
Introduction
Fanconi anemia (FA)1 is a rare inherited hematological disorder biologically char-
acterized by hypersensitivity to DNA cross-linking agents. FA is mainly an autoso-
mal recessive disease (except the rare X-linked FANC-B form), which was first
reported in 1927 by the Swiss pediatrician Guido Fanconi as familial, infantile ane-
mia.2 FA is now defined as a chromosomal instability (CI) syndrome, and it shows
a wide clinical and genetic heterogeneity. Indeed, genetically FA can be caused by
mutations in at least 18 different genes, mostly cooperating in a pathway which has
not yet been fully elucidated. These gene products somehow interact with proteins
encoded by genes which, when mutated, cause other CI syndromes, such as Ataxia
Teleangiectasia, Bloom syndrome, and Nijmegen Breakage Syndrome.3 All these
proteins cooperate in a pathway  which appears to be involved in DNA and oxida-
tive stress damage repair.4 The FA cellular phenotype is characterized by a G2 cell
cycle phase delay5 and by CI, typically appearing as characteristic rearrangement
figures (triradial and quadriradial figures made by non-
homologous chromosomes). The CI is both spontaneous6
and/or induced by alkylating DNA cross-linking agents,
such as mytomicin C (MMC)7 or the more specific
diepoxybutane (DEB);8 the cytogenetic DEB-test makes
the FA diagnosis possible in those patients not showing
typical malformations or still asymptomatic, and also in
patients not showing spontaneous CI at standard cytoge-
netic evaluation.
The phenotype of FA patients is largely heterogeneous,
since the natural history of the disease entails different
clinical manifestations which may either be present at
birth, or develop later during the course of the disease.
Clinically, FA patients present bone marrow failure at var-
ious times in life, typically beginning in childhood as
platelet deficiency, and then progressing to pancytopenia,1
eventually leading to life-threatening complications. FA
patients can show variable congenital malformations9 and
are prone to hematologic and solid neoplasias, which are
ultimately the leading cause of death.1,4,10-12 At present,
hematopoietic stem cell transplantation (HSCT) repre-
sents the only effective treatment for FA,13 although unfor-
tunately it cannot improve the patient’s growth rate or
reduce the propensity to develop non-hematological can-
cers.
FA is a rare disease, with an incidence rate of 0.1-0.5
new cases for every 100000 newborn children;1,14 thus,
large multicenter studies are needed to better describe the
natural history of the disease. Ideally, to prevent any bias,
such studies should include all patients diagnosed with FA
in a broad but well-defined geographic area, possibly with
a prospective collection of data and an adequate long-term
follow-up. Until now, the most reliable data on FA has
come from the International Fanconi Anemia Registry
(IFAR)15,16 and some national Registries, mostly the North
American Survey of Fanconi Anemia (NAS)12,17 and the
German Fanconi Anemia Registry (GEFA).18 In a rare and
highly heterogeneous disease such as FA, it is very difficult
to establish the natural history of the disease, and even
more difficult to organize research projects which require
the collection of samples from patients showing common
features. Moreover, some significant differences are possi-
ble among different populations, due to the existence of
geographic isolates or genetic derives. A specific national
registry, collecting patients’ clinical, epidemiological,
genetic and familial data, becomes a powerful tool, which
creates for physicians and the scientific community the
possibility of better knowing the disease, hence prevent-
ing misdiagnosis and delayed diagnosis.  A national reg-
istry also creates a network that facilitates the participa-
tion of patients in research projects and clinical trials.
To fulfill the need for a National Database including
most (if not all) FA patients diagnosed in Italy, in 1994 some
of us started “Il Registro Italiano Anemia di Fanconi” (RIAF),
which translates as 'The Italian Fanconi Anemia Registry'.19
This project was established within the Italian Public
National Health System (NHS), at the Genetic Unit of the
local health unit “ASL Napoli 1”, taking advantage of their
established expertise in diagnostics and genetic counseling
for CI syndromes. The aims of the project were: i. to create
a National database, recording all Italian FA cases; ii. to col-
lect information about the epidemiology of FA in Italy, as
well as about its natural history and therapeutic interven-
tions; iii. to promote a robust scientific network among
health workers (physicians, but also scientists) dealing
with FA in Italy, eventually increasing awareness about the
disease and promoting the strongest possible collaboration
among Italian physicians and scientists; iv. to provide
patients and their families with an established national net-
work for the diagnosis, treatment and follow-up of FA
patients; v. to share with the Italian authorities all the infor-
mation above, aiming to assess the real impact of FA on the
Italian NHS, eventually promoting further health policy
strategies. Herein we report on the 20-year experience of
this Registry, focusing on the natural history of the disease,
frequent therapeutic modalities and long-term outcomes of
FA patients. The major aim of this work was to identify
possible factors affecting the survival of FA patients, as well
as to identify possible changes in outcome emerging over
the two decades of this study.
Methods
Study design and data handling
The RIAF was officially established in 1994 as a prospective,
non-interventional study, approved by the local Government
(serving as the institutional review board, IRB) and operated
according to National laws within the NHS. The program was
approved and funded by the Regional Government (Regione
Campania), and supported by the Italian Association for Research
on Fanconi Anemia (AIRFA). All patient data were collected
through dedicated case report forms (CRFs), designed by the
geneticists working at the ASL Napoli 1, and further developed
thanks to the contributions of collaborating physicians (listed in
the Appendix). In accordance with the Declaration of Helsinki,
before enrollment all patients or their parents/guardians gave writ-
ten, informed consent, after discussing the RIAF aims and policy
and their own rights with an authorized delegate (geneticist or
physician), as listed in a written information sheet. Follow-up
CRFs were periodically filed by the geneticists or the physicians,
through a continuous sharing of critical information with both
treating physicians and patients or their families. The CRFs and
informed consent were approved by the local Government/IRB.
The data were stored both on paper and in digital records, strictly
protected, accessible only to the authorized staff and always made
anonymous for publications or sharing with other researchers.
Inclusion criteria, enrollment and data collection
Patients were enrolled only after a positive DEB or MMC test,
for the most part carried out or confirmed in our laboratory. The
chromosome breakage assay was always performed on peripheral
blood cells. Patients were enrolled either at the time of initial diag-
nosis, or later, during the course of the disease, according to
patients’ and/or parents’ decisions. Following informed consent,
family history and medical information were recorded by the
treating physicians, according to the specific CRFs. Given the epi-
demiologic purpose of the RIAF, the data of patients belonging to
non-Italian ethnic populations were collected separately and are
not considered here. Indeed, the patients geographic designation
was established on the basis of their parents’ and grandparents’
birthplaces (Caucasian ethnicity and proven Italian descent cover-
ing at least two generations); the same criteria were used to assign
a patient to a specific Italian Region. 
Data analysis and statistics
Statistical analysis was performed on the population of 180
patients (fetal losses and miscarriages were excluded), focusing on
the following categories: family history, disease presentation,
hematologic manifestations, HSCT, treatment impact on survival,
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malignancies, overall and cancer-free survival, and causes of death.
Standard descriptive statistical tests were applied as appropriate,
using SPSS software (PSP, Bologna, Italy). Student’s t-test, Mann-
Whitney test and Fisher’s exact test were used for most descriptive
analysis. The time to developing specific disease presentation (i.e.,
hematological presentation, hematological malignancies, solid
tumors) was presented as cumulative incidence, using a competing
risk approach, with birth treated as the FA onset date; death and
HSCT (the latter only for hematological presentation and hemato-
logical malignancies) were considered as competing risks. The
Kaplan-Meier curve was used to estimate overall survival; again
birth was considered as the FA onset date. The following variables
were tested for a possible impact on survival: gender, date of birth,
age at diagnosis, all congenital abnormalities (presence, total num-
ber, type; with and without skin abnormalities), hematological
presentation (at diagnosis, or at any time), hematological malig-
nancies, solid tumors (all together and head/neck) and HSCT.
Univariate and multivariate analyses were performed using a Cox
regression model on all patients, as well as separately on trans-
planted and non-transplanted patients.
Results
Diagnosis and genetics of FA
A preliminary diagnosis of FA was made by treating
physicians, based on clinical presentation at birth, or later
on; in some patients their family history was the main rea-
son to hypothesize the presence of FA. The diagnosis of
FA was based on a standard chromosome breakage test by
exposure to DEB or MMC, performed on peripheral blood
samples. Given the possible challenges in the diagnosis of
CI, all tests were confirmed at the Genetic Unit of the ASL
Napoli 1, or other laboratories with specific expertise for
the diagnosis of FA, eventually limiting subjective inter-
pretations and inter-laboratory technical variability.
Lymphoblastoid cell lines were established for research
aims and as diagnostic positive controls. A single DEB test
was sufficient for the diagnosis in the majority of cases;
however, the protocol adopted at the Genetic Unit of the
ASL Napoli 1 was used to confirm the diagnosis on two
different samples, allowing a robust consistency of data.
Between 1989 and 2014, out of a total of 1340 DEB tests
performed on 1185 subjects, the number of positive tests
was 206 (for 135 patients). Notably, a prior misdiagnosis
was proven in 11 patients: in 7 cases a previous diagnosis
of FA was not confirmed, whereas in 4 patients the diag-
nosis of FA was missing. Mosaicism was suspected in 9%
of patients.20 They showed chromosome breaks in <40%
of their cells, but typical DEB-induced rearrangements
were demonstrated; CI testing performed on different tis-
sues, together with clinical, family and/or molecular data,
confirmed the FA diagnosis. Patients lacking a confirmato-
ry positive chromosome breakage test were not enrolled
in the RIAF, irrespective of their clinical presentation; thus,
possible revertant phenotypes may be underrepresented
in this cohort. Complementation groups were available
for 55 patients; the most common complementation
group was A (91%), followed by G (5%) and D2 (4%)
(Online Supplementary Table S1).
Subject characteristics
Between 1994 and 2014, a total of 180 patients were
included in the RIAF, belonging to 151 distinct families
(median number of affected subjects per family was 1,
range 1-4; Table 1); a few (n=3) cases of miscarriage diag-
nosed as FA (by DEB and/or molecular tests on amnio-
cytes or chorionic villi) were also recorded, but were not
included in this study. The geographical distribution was
spread throughout the country, even if a significant num-
ber of patients were from the North-East or the South of
Italy;21 however, we were unable to identify any founder
effect. The characteristics of enrolled patients are
described in Table 2. There were 94 (52%) male and 86
(48%) female patients, with no statistical difference in
gender. The median age at diagnosis was 7.48 years; when
patients were divided according to the date of birth, by
quartiles (≤1980, 1981-1987, 1988-1995, ≥1996), the age at
diagnosis was significantly lower in patients born in more
recent periods (Mann-Whitney test, P<0.001; Figure 1A).
Family history
Family history was carefully collected for all patients
included in the registry; parents consanguinity was record-
ed in 20 of the 151 families (14%; Table 1). For each family
(considered as two parents), the median number of affect-
ed children was 1 (range 1-4), the median of unaffected
siblings (all confirmed by DEB test: all alive siblings were
tested even as potential HSCT donors) was 1 (range 0-10);
the median of miscarriages was 0 (range 0-3). Globally, in
the 151 families enrolled we recorded 310 babies, of
whom 183 (60%) were FA cases (180 enrolled in the RIAF
and 3 miscarriages), and 127 were unaffected siblings.
Thirty-seven of the patients included in the registry
reported a family history of FA. We also looked for the
occurrence of hematological disorders and malignancies in
the relatives of enrolled FA patients (up to the second
degree of kinship); family history for cancer (taking into
account up to the second degree) was 56% (85 out of 151).
Family history for hematological disorders was demon-
strated in 19% of patients. Morphological abnormalities in
some relatives were recorded in 19% of patients.
Disease presentation
In the majority of patients the diagnosis was suspected
based on typical morphological and/or hematological
abnormalities and/or growth retardation. As detailed in
The Italian Fanconi Anemia Registry
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Table 1. Characteristics of the 151 families.*
Variable                                                                       151 Families (%)
Consanguinity between parents            None                               131 (86)
                                                                       1st degree                         13 (9)
                                                                       2nd degree                         3 (2)
                                                                      >2nd degree                      4 (3)
N. of affected children°                          1                                       124 (82)
                                                                       2                                        22 (14)
                                                                       3                                          4 (3)
                                                                      4                                          1 (1)
N. of not affected children                     0                                        35 (23)
                                                                       1                                        65 (43)
                                                                       2                                        36 (24)
                                                                      3 or >3                            15 (10)
N. of miscarriages                                     0                                                                122 (81)
                                                                       1                                        21 (14)
                                                                                                                       2                                          7 (5)
                                                                      3 or >3                             1 (<1)
*For this analysis, a family is intended as two parents with their children; data are
expressed by family; °including abortions with confirmed FA.
Table 2, congenital abnormalities were demonstrated in
90% of patients at the time of diagnosis; the most com-
mon were the typical abnormalities of skin pigmentation,
which affected 96% of RIAF patients (Table 2); skeletal
abnormalities were also very frequent (57%). Other com-
mon congenital abnormalities involved growth retarda-
tion (39%), the central nervous system (35%), the urinary
system (34%), the genital tract (18%), the gastrointestinal
tract (13%), the eyes (12%), the endocrine system (9%) or
the cardiovascular system (7%). Hematological manifesta-
tions were defined according to the definition of aplastic
anemia22 and in accordance with the WHO 2008 classifica-
tion of myeloid malignancies.23 The majority of patients
(77%) exhibited some hematological abnormalities at
diagnosis, which in most cases was a mild-to-moderate
cytopenia eventually associated with some degree of bone
marrow failure (BMF), whereas hematological malignan-
cies (e.g., myelodysplastic syndromes, MDS) and solid
tumors were very rarely observed at diagnosis (Table 2).
Thanks to the long-term follow-up of the enrolled
patients, we were able to assess the further course of the
disease with the development of the most common com-
plications of FA, as well as the impact of different factors
on survival.
Time to hematological manifestations: bone marrow
failure and hematological malignancies
Even if hematological abnormalities were present at
diagnosis in only 77% of cases, a total of 172 (96%) of FA
patients enrolled in the RIAF had some hematological
manifestations during their disease course; in almost all
cases (172, 96%) this included cytopenia due to BMF,
whereas a hematological malignancy (mostly MDS or
acute leukemia, n=9 and n=4, respectively) was recorded
in 8% of patients (see Table 3). As expected, in many
cases an initial BMF progressed to either MDS or more
aggressive hematological cancers; 1 MDS, 1 leukemia and
1 lymphoma patient did not evolve from a previous BMF.
Considering death and HSCT as competing events, the
cumulative incidence of any hematological disorder was
62%, 88% and 94% at 10, 20 and 30 years respectively,
whereas the incidence of hematological malignancies was
5%, 8% and 22% at 10, 20 and 30 years, respectively.
'The cumulative incidence of the first hematological pres-
entation and of the first hematological malignancy is
depicted in Figure 1B.
Time to hematopoietic stem cell transplantation
The development of a hematological presentation is the
main indication for HSCT in FA patients; indeed, more
than half of the patients enrolled in the RIAF (102 out of
180, 57%) had received a HSCT from either a non-affect-
ed sibling or matched unrelated donor (Table 3). The first
HSCT was performed from a non-affected sibling in 38%
of cases, from a matched unrelated donor in 48%, and
quite rarely from cord blood (4%) or a mismatched related
donor (0.9%). The cumulative incidence of HSCT in our
patient cohort was 33%, 64% and 72% at 10, 20 and 30
years, respectively, as depicted in Figure 1B. The age at
transplant was significantly different according to the date
of birth cohorts, since patients born in more recent years
were transplanted earlier (Mann-Whitney test, P<0.001;
Figure 1C). Since National and European Registries collect-
ing transplant-specific information exist,15,16 in the RIAF we
decided not to duplicate this information. A formal analy-
sis of HSCT outcome in these patients is beyond the scope
of this study. However, follow-up data on survival and the
possible development of malignancies were also collected
for those RIAF patients who received a HSCT.
Cumulative incidence of solid tumors
A total of 27 solid cancers were diagnosed in 20 of the
180 RIAF patients (11%); a few patients experienced mul-
tiple cancers. The most common sites of cancer were the
head and neck (n=12, 44% of all solid tumors), liver (n=3,
11%), breast, thyroid and genital tract (n=2 for each, 7%)
(see Table 3 for details). The cumulative incidence of solid
tumors was 1%, 15% and 32% at 10, 20 and 30 years
respectively, as depicted in Figure 1B. The incidence of all
solid cancers and of head and neck tumors was not statis-
tically different between patients who had received a
HSCT and those who had not (P=0.43 and P=0.50, respec-
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Table 2. Patient characteristics at diagnosis.
Variable                                                                         180 Patients (%)
Gender                                                                                                             
Female                                                                                                   86 (48)
Male                                                                                                       94 (52)
Age (median years at diagnosis)                                                  7,48 (0-37,7)
Family history
no                                                                                                           143 (79)
yes                                                                                                           37 (21)
Family history for malformations
no                                                                                                           145 (81)
yes                                                                                                           35 (19)
Family history for hematological diseases
no                                                                                                           145 (81)
yes                                                                                                           35 (19)
Family history for cancer
no                                                                                                            79 (44)
yes                                                                                                          101 (56)
Congenital abnormalities                                                                          
none/unknown                                                                                     17 (10)
skin only                                                                                                 16 (9)
structural abnormalities*                                                               147 (81)
Type of malformation                                                                                   
skin hyper- hypopigmentation                                                        163 (96)
skeletal abnormalities                                                                      103 (57)
growth retardation                                                                              70 (39)
central nervous system                                                                       63 (35)
renal and urinary tract                                                                       61 (34)
genital tract                                                                                          33 (18)
gastrointestinal tract                                                                          23 (13)
eyes                                                                                                         21 (12)
endocrine system                                                                                  16 (9)
cardiovascular system                                                                         12 (7)
Hematological disease                                                                               
BMF*
no                                                                                                            42 (23)
yes                                                                                                          138 (77)
Hematological malignancies^
no                                                                                                           179 (99)
yes                                                                                                             1 (1)
Solid tumors
no                                                                                                           177 (98)
yes                                                                                                             3 (2)
*As defined according to the International Agranulocytosis and Aplastic Anemia Study
Group; ^As defined according to the WHO 2008 criteria.
tively; Figure 1D), even if the analysis is limited by the
small number of events. In transplanted patients, all but
one tumor occurred after HSCT.
Overall survival and prognostic factors
Ninety-four of the 180 patients were still alive at the time
of the last follow-up. For all patients enrolled in the RIAF,
overall survival was calculated starting from the day of
birth. With a median follow up of 15.6 years, median sur-
vival was 22.5 years (Figure 2A); probabilities of survival at
10, 20 and 30 years were 88%, 56% and 37%, respectively
(without censoring HSCT patients). Looking for the natural
history of the disease, when patients who had received an
allogeneic HSCT were censored at the time of transplant,
the probabilities of survival at 10, 20 and 30 years were
85%, 39% and 24%, respectively (Figure 2B). In univariate
analysis, no patients feature affected overall survival, except
age at diagnosis and the number of structural abnormalities
(excluding skin anomalies; Online Supplementary Table S2).
In multivariate analysis, an older age at diagnosis
(HR=0.873, P<0.001) and the presence of more than 10
structural abnormalities (excluding skin; HR=6.504,
P=0.017) were associated with a better or worse survival
rate, respectively. This distinction resulted in statistically
significant differences in overall survival based on age at
diagnosis (Figure 2C; P<0.001) and on higher numbers of
structural abnormalities (Figure 2D; P<0.005). Notably, BMF
at initial presentation, date of birth cohorts and HSCT
seemed not to affect survival (Table 4). Indeed, looking at
overall survival by quartiles of date of birth there was no
improvement in survival over time (Figure 2E; P=n.s.).
Similarly, grouping patients by HSCT, the 10, 20 and 30
year survival rate of non-transplanted patients (n=78, medi-
an follow-up 15.8 years) were 84%, 49% and 34%, respec-
tively, while those of transplanted patients (n=102, median
follow-up 16 years) were 90%, 62% and 40%, respectively
(Figure 2F; P=0.17). Multivariate analysis was also per-
formed separately on non-HSCT and HSCT patients; in this
context, age at diagnosis remained associated with a better
survival rate in both groups (Online Supplementary Table S3).
Cause of death
Eighty-six of the 180 FA patients enrolled in the RIAF
died during their follow-up; the main causes of death are
listed in Table 5. As expected, the causes of death were
different in patients who had not received an HSCT as
compared with those of transplanted patients (P<0.001;
Chi-square test). Indeed, in non-HSCT patients the main
causes of death were related to the underlying disease (i.e.,
for the most part the hematological abnormalities), such as
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1. Time to most common FA complications. (A) Age at diagnosis, according to quartiles of date of birth (DOB); (B) Cumulative incidence of bone marrow failure (BMF),
hematological malignancies (MDS and AML; HEM TUM), solid tumors (SOL TUM) and HSCT; (C) Age at HSCT, according to DOB quartiles; (D) Cumulative incidence of
solid tumor and of head/neck tumors: HSCT vs. no HSCT.
A B
C D
infections (n=14, 33% of total deaths in non-HSCT
patients), bleeding (n=8, 18.5%) and solid tumors (n=9,
21%). In contrast, in HSCT patients the majority of deaths
were somehow related to treatment complications, such
as infections (n=11, 25.5% of total deaths in HSCT
patients), graft versus host disease (GvHD) (n=11, 25.5%)
and other transplant related mortality (TRM) (n=13, 30%).
Solid tumors accounted for 9% of deaths (n=4). 
Discussion
The RIAF is the first population-based Italian database,
run within the Italian NHS, focusing on FA, which is rare
in the frequency of the disease, but the most common
among inherited bone marrow failure syndromes. Herein
we report a comprehensive analysis of all patients includ-
ed in the registry over the past 20 years with their long-
term follow-up, eventually providing a reliable description
of the natural history of FA. In our series of 180 prospec-
tively collected patient data, we have shown a median sur-
vival of 22 years, which unfortunately has not improved in
the past two decades. Our efforts of creating a robust sci-
entific network have increased the awareness of this dis-
ease in Italy, eventually leading to objective achievements.
Indeed, the diagnosis has come to be made earlier over the
past decades, and the time to the only curative treatment
– namely HSCT – has decreased. Nevertheless, these
improvements in the management of FA patients have not
yet resulted in a better survival rate, and even the outcome
of patients who have received a HSCT does not appear to
be better than that of those who did not. Indeed, in our
multivariate analysis, the only factors associated with a
better outcome were an older age at diagnosis and a lower
number of structural abnormalities, indicating that differ-
ent clinical phenotypes may have a different life expectan-
cy.
The natural history of FA has been described in previous
retrospective studies,15-18 which have highlighted the het-
erogeneity of clinical presentation. The RIAF includes only
patients with a DEB test confirmed diagnosis of FA, who
are unselected for specific disease presentations and have
a long-term follow-up. Thus, selection biases (e.g., toward
a severe phenotype) should be limited (with the only
exception being a possible underestimation of patients
beginning with cancers, who might not receive the correct
FA diagnosis), eventually leading to a more accurate repre-
sentation of the natural history of FA. However, like all
registry studies, the RIAF suffers from potential limita-
tions, since its completeness and accuracy largely depends
on the commitment and dedication of collaborating physi-
cians. Our database confirms that FA severely impairs the
survival of affected patients; the median survival observed
in our series (about 22 years) was slightly lower than those
reported by the International Fanconi Anemia Registry16
and by the USA National Cancer Institute.24 In our
Registry, we have not systematically investigated any
genotype-phenotype correlation;25 however, genetic data
from a subset of patients (as well as independent data on
the genetics of FA in the same geographic area)26 seem pre-
dominantly influenced by the large prevalence of patients
harboring FANCA mutations.21,27 Malignancies play an
important role in the natural history of FA, the risk increas-
ing with age for a wide array of cancer types;10-12,18 more-
over, some patients can develop multiple cancers, possibly
also due to the increased risk associated with anti-cancer
treatments (i.e., chemotherapy and radiotherapy). This
report confirms the cancer propensity of FA patients and
further stresses the need for frequent and careful tumor
evaluations, aiming at early therapeutic interventions,24,28
the only effective strategy for improving long-term sur-
vival in FA patients.
Our Registry was not designed to formally investigate
the impact of specific therapeutic interventions on the nat-
ural history of the disease. However, even if a head-to-
head comparison is impossible, we have separately looked
for overall survival in FA patients who have received an
HSCT, without showing any difference with non-trans-
planted patients. HSCT may cure the hematological dis-
ease associated with FA, but it does not reverse the pheno-
type that results from the involvement of extra-hemato-
logical tissues and organs.29-31 This is especially true for the
intrinsic risk of cancer due to the genetic instability typical
of FA, which might actually be increased by the pre-trans-
plant conditioning regimen and possible detrimental
A.M. Risitano et al.
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Table 3. Disease manifestations during the whole disease course.
Variable                                                                    180 Patients (%)
Hematological disease                                                                          
BMF
     no                                                                                                      8 (4)
      yes                                                                                                 172 (96)
Hematological malignancies
      no                                                                                                   166 (92)
      yes                                                                                                   14 (8)
      MDS                                                                                               9 (5)
      AML                                                                                              4 (2.5)
     Lymphoma                                                                                 1 (0.5)
Solid tumors
      no                                                                                                   160 (89)
      yes                                                                                                  20 (11)
Sites of solid tumors°                                                                         
      head/neck                                                                                   12 (7)
      liver                                                                                               3 (2)
      breast                                                                                           2 (1)
      thyroid                                                                                          2 (1)
      genital tract                                                                                 2 (1)
      lung                                                                                              1 (0.5)
      central nervous system                                                             1 (0.5)
      kidney                                                                                         1 (0.5)
      soft tissues                                                                                 1 (0.5)
      skin                                                                                             1 (0.5)
     gastrointestinal tract                                                               1 (0.5)
HSCT                                                                                                          
      no                                                                                                  78 (43.5)
      yes                                                                                                102 (56.5)
      Sibling                                                                                       39* (22)
      MUD                                                                                           49§ (27)
      CBU                                                                                               4 (2)
      Haploidentical                                                                          1 (0.5)
     Unknown                                                                                     9 (5)
Alive                                                                                                            
      yes                                                                                                  94 (52)
      no                                                                                                  86 (48)
°The total number of tumors exceeds the number of patients with cancer, since some
patients experienced multiple tumors: one patient had 4 tumors (genital tract, breast,
skin and head/neck), 4 patients had 2 tumors (head/neck and gastrointestinal tract,
head/neck and liver, head/neck and thyroid, central nervous system and Wilms). *2
from sibling cord blood units. §One was a second HSCT after a graft failure of a first
HSCT from a sibling donor
effects of GvHD.28,32 Notably, in our study the risk of solid
tumors remains high even after HSCT, but apparently it is
not increased over that of non-transplanted patients.
However, these data should be confirmed with a longer
follow-up, possibly within International studies designed
to specifically investigate this endpoint.  Our observation
that the survival of transplanted and non-transplanted
patients was not different is not surprising, because HSCT
in the context of FA carries specific challenges. Beyond the
fact that HSCT does not affect the extra-hematological
phenotype of FA, other reasons may play a role: i. HSCT
patients may be biased toward a more severe phenotype;
ii. initial patients may have received a HSCT with a non-
optimized conditioning regimen;33 iii. initial patients have
received HSCT quite late in their disease course; and iv.
longer follow-up is needed to let the positive impact of
HSCT emerge. Unfortunately, even if in recent decades
improvements in transplant procedures (e.g., the use of
reduced intensity conditioning regimens) have significant-
ly prolonged the overall survival rate of patients,31 HSCT
for FA remains associated with a poor prognosis, with a
high number of patients exposed to lethal complications.
Since the RIAF was not designed to study HSCT in the
context of FA, the actual impact of HSCT on the natural
history of FA needs to be investigated in more specific
studies that also deal with all the transplant-specific fac-
tors affecting the outcome of HSCT. Indeed, the question
is whether more recent HSCT, performed according to
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Figure 2. Overall survival. (A) Overall survival, HSCT not censored (filled area represents 95% confidence interval); (B) Overall survival, HSCT censored (filled area
represents 95% confidence interval); (C) Overall survival, according to age at diagnosis (patients were grouped based on the median age at diagnosis of 7,48 years);
(D) Overall survival, according to number of structural abnormalities; (E) Overall survival, according to DOB quartiles (HSCT not censored); (F) Overall survival: HSCT
vs. no HSCT.
A
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transplant protocols which have been optimized over the
past years,34 have improved the outcome of FA, as com-
pared with natural history. One may anticipate that com-
bining earlier therapeutic intervention with improved
HSCT protocols may lead in the near future to improved
long-term outcomes for FA patients,35,36 especially if a lack
of an increased risk of malignancies is confirmed.
In conclusion, our registry confirms the adverse natural
history of FA, eventually leading to disappointing out-
comes that have not improved over time; thus, there is an
urgent need for effective treatment strategies. Our findings
highlight that large collaborative studies are essential to
investigate the impact of available therapeutic interven-
tions (such as transplantation), to optimize their use and to
define their role in the treatment algorithm of FA. It seems
obvious that it will only be through stronger collaboration
among physicians and scientists, National and
International Registries, and healthcare networks, that we
may hope to offer better long-term outcomes to  patients
affected by FA and to their families.  
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Ist. “G. Gaslini” - Dufour C., Svahn J. (15); Padova -
Oncoematologia Pediatrica AOU - Bisogno G., Cesaro S.,
Rosolen A., Rossetti F., Sainati L.,Varotto S. (14); Torino - Dip.
Scienze Pediatriche e dell’Adolescenza OIRM - Ramenghi U.
(14); Napoli - Clinica Pediatrica AOU SUN - Nobili B.,
Matarrese S., Ferrara M., Perrotta S. (14); Roma - Ematologia
Univ. "La Sapienza" - Mandelli F, Giona F., Arcese W., Rana I.,
Amendola A., Barberi W., Testi A.M. (12); Cagliari - Centro
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Table 4. Multivariate analysis.
Variable HR 95% CI (lower) 95% CI (upper) P
Gender 1,067 0,643 1,772 0,802
Date of birth (quartiles) - - - 0,305
Age at diagnosis 0,873 0,821 0,928 <0,001
Congenital abnormalities (n>10,  except skin) 6,504 1,406 30,086 0,017
Skin hyper- hypopigmentation 0,665 0,394 1,125 0,128
Skeletal abnormalities 1,093 0,548 2,18 0,8
CNS and/or eyes abnormalities 0,84 0,377 1,873 0,67
Renal and urinary tract abnormalities 1,163 0,589 2,298 0,663
Genital tract abnormalities 0,778 0,365 1,659 0,516
Gastrointestinal tract abnormalities 1,523 0,677 3,426 0,31
Endocrine  abnormalities 0,619 0,246 1,563 0,311
Cardiovascular  abnormalities 0,399 0,129 1,234 0,111
BMF at diagnosis 1,846 0,757 4,504 0,178
BMF anytime 0,823 0,171 3,964 0,808
Hematological malignancies 1,7 0,813 3,558 0,159
Solid tumours 0,595 0,294 1,204 0,149
HSCT 0,724 0,403 1,301 0,28
Table 5. Causes of death.
Cause No HSCT (%) HSCT (%) Total (%)
Infections 14 (33) 11 (25.5) 25 (29)
Bleeding 8 (18.5) 0 (0) 8 (9.5)
Tumor 9 (21) 4 (9) 13 (15)
Liver failure 1 (2) 0 (0) 1 (1)
Kidney failure 2 (5) 0 (0) 2 (2.5)
Heart failure 1 (2) 0 (0) 1 (1)
GvHD 0 (0) 11 (25.5) 11(13)
Other TRM 0 (0) 13 (30) 13 (15)
Other  0 (0) 1 (2) 1 (1)
Unknown 8 (18.5) 3 (7) 11(13)
43 43 86
Trapianti Osp. Microcitemico - Arru L., Cossu F. (8); Monza -
Oncoematologia Pediatrica Policlinico "San Gerardo" - Longoni
D. (8); Napoli - Ematologia AOU "Federico II" - Rotoli B.,
Catalano L., Fiorillo A., Risitano A. (7); Pescara - UOC
Trapianto Emopoietico PO - Di Bartolomeo P. (5); Palermo -
Ematologia Osp. "Cervello" - Fabbiano F., Mirto S. (5); Palermo
- Oncoematologia Pediatrica Osp.“Di Cristina” - Farruggia P.
(4); Roma - Pediatria Osp. “Sant'Eugenio” - Del Principe D. (4);
Bologna - Oncoematologia Pediatrica "Sant'Orsola" - Rosito P.,
Paolucci G. (3); Catania - Ematologia ed Oncologia Policlinico di
Catania - Schilirò G. (3); Parma - Pediatria e Oncoematologia
Pediatrica A.O. - Izzi G., Barone A. (3); Napoli - Dip. Pediatria
AOU “Federico II” - Pignata C., Sebastio G., Scarcella A. (2);
Napoli - Pediatria AO “A. Cardarelli” - Saviano A. (2); Nocera
Inferiore - Pediatria AO “Umberto I” - Amendola G., Di
Concilio R. (2); Pesaro - Pediatria Osp. "San Salvatore" - Felici
L. (2); Roma - Oncoematologia pediatrica Policlinico "A.
Gemelli" - Lasorella A., Mastrangelo S. (2); Trieste - Emato-
oncologia Pediatrica Univ. - Rabusin M. (2); Ancona -
Oncoematologia Pediatrica - Pierani P., Fabrizzi B. (2); Avellino
- Ematologia AORN "San Giuseppe Moscati" - Volpe E.,
Cantore N. (2); Bari - Dip. Biomedicina Età Evolutiva UO
Pediatrica I Policlinico - Martire B. (2); Catanzaro - Ematologia
PO "Pugliese-Ciaccio" - Levato L. (1); Ferrara - Clinica
Pediatrica Univ. - Borgna Pignatti C. (1); Genova - Div.
Pediatria "Ospedali Galliera" - Melevendi C. (1); Perugia -
Pediatria AO - Mazzarino I. (1); Pisa - Oncoematologia
Pediatrica AO - Favre C., De Marco E. (1); Reggio Calabria -
Genetica Medica OORR “Bianchi-Melacrino” - Laganà C. (1);
Roma - UOC TCS Policlinico “Tor Vergata” - Cudillo L. (1);
Siena - Italy -Clinica Pediatrica Univ. - Acquaviva A. (1); Zurich
(Switzerland) - Kinderspital – Albisetti M. (1).
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New transplant approaches are urgently needed for patients with refractory severe aplastic anemia (SAA)
who lack a matched sibling or unrelated donor (UD) or who have failed UD or cord blood transplant. Patients
with refractory SAA are at risk of later clonal evolution to myelodysplastic syndrome and acute leukemia. We
report our pilot ﬁndings with haploidentical hematopoietic stem cell transplantation (haploHSCT) using
uniform reduced-intensity conditioning with postgraft high-dose cyclophosphamide in 8 patients with re-
fractory SAA or patients who rejected a prior UD or cord blood transplant. Six of 8 patients engrafted. Graft
failure was associated with donor-directed HLA antibodies, despite intensive pre-HSCT desensitization with
plasma exchange and rituximab. There was only 1 case of grade II skin graft-versus-host disease. We show
that haploHSCT can successfully rescue refractory SAA patients who lack donor-directed HLA antibodies but
not in the presence of donor-directed HLA antibodies. This novel protocol for haploHSCT for SAA has been
adopted by the European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working
Party for a future noninterventional, observational study to further evaluate its efﬁcacy.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Patients with severe aplastic anemia (SAA) who lack a
matched sibling or unrelated donor (UD) and who fail to
respond to immunosuppressive therapy are at increased risk
of death from infection and hemorrhage and later clonal
evolution to myelodysplastic syndrome and acute myeloid
leukemia. Risk factors for myelodysplastic syndrome/acute
myeloid leukemia include olderage, short telomeres, presence
of monosomy 7, prolonged use of granulocyte colony-
stimulating factor (G-CSF), and multiple courses of immuno-
suppressive therapy [1-5]. Hence, there is a need to explore
alternative donor hematopoietic stem cell transplantation
(HSCT) using either a haploidentical family donor [6-12] or
cord blood [13,14], because this is a potentially curative option.
However, most studies report poor outcomes, due to poor
engraftment, and high risk of graft-versus-host disease
(GVHD) with haploidentical HSCT (haploHSCT). Attractions
of haploHSCT are graft availability for most patients, lessdgments on page 1715.
equest: Professor Judith C. W. Marsh,
dicine, King’s College Hospital, Denmark
hs.net (J.C.W. Marsh).
2014 American Society for Blood and Marrow
14.06.028expensive procedural cost than cordHSCT, and shorter time to
procurement of the graft. However, published data are limited
and mostly restricted to children and young adults [7-11].
Post-transplant cyclophosphamide (CY) has been used in
haploHSCT for hematological malignancies to selectively
deplete donor alloreactive T cells and thereby reduce acute
GVHD [15,16]. In the setting of aplastic anemia, high-dose
CY without stem cell support can salvage a signiﬁcant
proportion of refractory patients, but this approach has not
been met with widespread enthusiasm because of pro-
longed pancytopenia after therapy [17]. A nonmyeloablative
regimen with postgraft CY was reported in 2 patients with
hemolytic paroxysmal nocturnal hemoglobinuria and 1 with
both paroxysmal nocturnal hemoglobinuria and sickle cell
disease, resulting in sustained engraftment and absence of
GVHD in 2 patients [11]. In 2011, Dezern et al. [18] reported
the ﬁrst use of post-transplant CY for GVHD prophylaxis in
2 high-risk SAA patients. They used matched sibling
donors and myeloablative conditioning, with both patients
engrafting and no GVHD [18]. The Hopkins group also re-
ported 17 cases using the mini-haploidentical approach
with post-transplant CY in sickle cell disease. There were no
cases of mortality or GVHD, but primary graft failure was a
problem [19].Transplantation.
J. Clay et al. / Biol Blood Marrow Transplant 20 (2014) 1711e17161712In this study we used a uniform conditioning regimen
using reduced-intensity conditioning with post-transplant
CY for haploHSCT in 8 SAA patients, 4 with refractory SAA
and 4 after failed UD or cord blood HSCT. We also used G-CSF
mobilized peripheral blood stem cells (PBSCs) instead of
bone marrow (BM) to achieve a high dose of infused CD34þ
cells for engraftment.
METHODS
Eight patients were transplanted, 4 had refractory acquired SAA and 4
failed to engraft after UD (n¼ 3) or cord blood (n¼ 1) HSCT. Of the 3 patients
who had failed previous UDHSCT, 2 had failed 2 previous UD transplants. Six
of 8 patients had acquired idiopathic SAA. Two patients had secondary
severe marrow aplasia, 1 after chemotherapy for Hodgkin disease and who
subsequently failed UD HSCT and 1 who failed 2 UD HSCTs for myelodys-
plastic syndrome. Median age was 32 years (range, 19 to 57) and median
disease duration 46 months (range, 6 to 91). Family donors were siblings
(n ¼ 5), parents (n ¼ 2), and children (n ¼ 1), and HLA matching was 5/10
(n ¼ 6) and 6/10 (n ¼ 2). Five patients were included in the previously re-
ported multicenter series [20].
Conditioning regimen was ﬂudarabine 30 mg/m2 (days 6 to 2), CY
14.5 mg/kg (days 6 and 5), and total body irradiation 2 Gy (day 1).
Unmanipulated G-CSFemobilized PBSCs were infused at a median CD34þ
cell dose of 6. 2106/kg (range,1.8 to 8.3). GVHD prophylaxis was CY 50mg/
kg/d (days þ3 and þ4), tacrolimus for 9 months maintaining trough drug at
10 to 15 mg/L with tapering between 9 and 12 months, and mycophenolate
15 mg/kg until day þ35.
Median follow-up of survivors was 14.8 months (range, 7.2 to 44.4).
Median Karnofsky and HCT-comorbidity index scores were 80% (range, 50 to
90) and 3 (range, 0 to 5), respectively. Neutrophil and platelet engraftment
and acute and chronic GVHD were deﬁned as previously reported [21].
Chimerism was assessed in unfractionated BM and peripheral blood CD3þ
T cells and CD15þ granulocyte populations. Full donor chimerism was
deﬁned as >95% donor hematopoietic cells and mixed chimerism as 5% to
95% cells [21,22]. All patients were screened for cytomegalovirus, Epstein-
Barr virus, and adenovirus at twice weekly intervals for the ﬁrst 3 months.
HLA antibodies were measured routinely pretransplant in all patients using
microbead ﬂow cytometry assay with mean ﬂuorescence intensity read-out
for serum antibody level.
RESULTS
Six patients had sustained neutrophil engraftment; me-
dian time to neutrophil engraftment was 18.5 days (range, 16
to 23), and 5 sustained platelet engraftment with a median
time of 26 days (range, 21 to 27) (Table 1). Full donor
chimerism in unfractionated cells and CD3 and CD15 line-
ageswas achieved andmaintained at last follow-up (Table 2).
These results are different from the pattern of chimerism as
previously reported from our group using ﬂudarabine, CY,
alemtuzumab (FCC) conditioning regimen for SAA patients
transplanted from sibling or matched UDs, where a high
incidence of mixed T cell chimerism in the presence of full
donor myeloid chimerism was observed, associated with a
very low incidence of chronic GVHD [22]. We therefore
compared BM trephine cellularity at days þ28 and þ100 and
at 1 year after haploHSCTwith results using FCC conditioning
for sibling and UD HSCT from our center. As seen in
Supplementary Figure 1, the median BM cellularity at each
time point was not signiﬁcantly different between the 2
groups.
Two patients (patients 6 and 8) who failed to engraft died
on days þ60 and þ137 from sepsis. Both had multiple HLA
antibodies directed against the donor which persisted at high
level despite treatmentwith rituximab (375mg/m2weekly for
4 weeks) and plasma exchanges pretransplant (Figure 1A,B).
In contrast, sustained engraftment occurred in patients with
no HLA antibodies. For patient 6, there was a reduction in
the HLA-B51, donor-directed, antibody level, but despite this
the patient failed to engraft. The second patient with mul-
tiple donor-directed HLA antibodies achieved a signiﬁcantreduction in antibody levels for 3 antibodies but not for HLA-
DR53 speciﬁc antibody.
Cytomegalovirus and Epstein-Barr virus viremia occurred
in 2 and 5 patients, respectively, but no cases of cytomega-
lovirus disease or Epstein-Barr virus post-transplant lym-
phoproliferative disorder occurred. There was no adenovirus
viremia. One patient developed Guillain-Barré syndrome
(patient 2) with no viral pathogens identiﬁed. No response to
intravenous immunoglobulin occurred, but some improve-
ment was found with plasmapheresis. During this episode
the patient required a prolonged period of intubation during
a 92-day intensive care unit admission, which was compli-
cated by recurrent respiratory infections with multiple or-
ganisms. At the time of death he was independent of platelet
transfusions with the use of eltrombopag and required RBC
transfusion approximately 6 weekly.
There was only 1 case of acute GVHD (grade II skin) and
no chronic GVHD; however, follow-up was short, with a
median follow-up of patients of 12.2 months (range, 3.2 to
40.4). The conditioning regimen was well tolerated, with no
hemorrhagic cystitis. One patient (patient 3) delivered a
healthy baby at term on day þ560 post-transplant. The
observation that this regimen does not appear to cause
gonadal failure is supported by a previous report of 2 suc-
cessful pregnancies using this regimen [23].DISCUSSION
We show in a small cohort of patients with aplastic ane-
mia that haploHSCT using a uniform, nonmyeloablative
conditioning regimen with post-transplant CY and with
PBSCs as stem cell source rather than BM is a feasible option.
Remarkably, the procedure was able to rescue all 4 patients
who had primary graft failure after a matched UD transplant
or cord blood HSCT, including 2 patients with nonengraft-
ment after 2 unrelated grafts. Furthermore, our patients had
a high HCT-comorbidity index and poor performance status.
This series includes 2 patients with secondary aplasia, 1 due
to chemotherapy for Hodgkin lymphoma. Although the
mechanism underlying the marrow failure in these 2 cases is
different from those with idiopathic SAA, these cases also
illustrate the efﬁcacy of this approach after failed matched
UD or cord blood donor HSCT in the presence of severe
pancytopenia and a hypocellular BM.
In contrast to our previous ﬁnding of mixed T cell
chimerism with sustained myeloid engraftment using
alemtuzumab-based conditioning for matched sibling and
UD HSCT for SAA, in this study we observed sustained donor
T cell and myeloid engraftment in all assessable patients. We
used G-CSFemobilized stem cells in preference to BM cells to
optimize the infused stem cell dose for halpoHSCT. Stem cell
dose is especially important in SAA, where there is an inverse
correlation between stem cell dose and graft rejection [24].
The concernwith PBSCs of an increased risk of GVHDwas not
borne out in our small series. We previously reported a high
incidence of mixed T cell chimerism with sustained myeloid
engraftment and a low incidence of chronic GVHD in SAA
patients transplanted from matched sibling donors or UDs
using the FCC conditioning regimen [22]. In contrast, in this
study of haploHSCT, we showed full donor T cell and myeloid
chimerism in engrafted patients. We therefore were inter-
ested to know if hematopoietic recovery was associated with
a higher degree of BM cellularity after haploHSCT compared
with FCC HSCT. However, we showed no signiﬁcant differ-
ence between the 2 groups, but the patient numbers in the
Table 1
Patient Characteristics and Outcomes
Patient No., Age (yr),
Gender/Donor
Disease and Severity Previous Therapy for Aplasia
Pre-HaploHSCT
Previous HSCT and
Outcome
HCT-CI/
Karnofsky Score
CD34 Stem Cell
Dose (106/kg)
Engraftment (Neutrophil
and Platelet)
GVHD (Acute
and Chronic)
Median Follow-Up
(mo)/Survival Status
1, 19, F/mother SAA-MDS ATG þ CSA  2, NR
ATG þ MMF, PR, relapse
MMF-NR
Double cord-GF 0/80 6.7 Day þ18
Day þ21
None 40.4/alive
2, 51, M/sister Therapy-related severe
aplasia for Hodgkin disease
ATG þ CSA, NR MUD-GF 3/70 4.5 Day þ18
No platelet engraftment
None 22/dead
Sepsis
3, 23, F/sister SAA/hPNH ATG þ CSA, PR, relapse None 3/80 5.8 Day þ16
Day þ26
Grade II
acute GVHD
Skin
12.2/alive
4, 57, F/brother SAA/hPNH ATG þ CSA, CR, relapse,
oxymetholone, eculizumab
eltrombopag
MUD-GF
MUD-GF and
Epstein-Barr virus PTLD
5/50 4.9 Day þ20
Day þ27
None 9.3/alive
5, 22, M/brother VSAA ATG þ CSA, NR None 1/90 6.9 Day þ23
Day þ27
None 3.2/alive
6, 20, M/father VSAA CSA, NR
ATG þ MMF, NR
oxymetholone, NR
danazol, NR
None 1/90 6.7 Non-engraftment
HLA antibody positive
None 2.1/dead
Graft failure/sepsis
7, 50, M/son Therapy-related severe
aplasia for MDS-RCMD
None MUD-GF
MUD-GF
4/50 8.3 Day þ19
Day þ25
100%
None 33.4/alive
8, 41, M/mother VSAA/PNH ATG þ CSA  2, CR, relapse  2,
oxymetholone, PR, relapse,
eculizumab
None 5/80 1.8 Nonengraftment
HLA antibody positive
None 3.1/dead
HCT-CI indicates HCT comorbidity index; MDS, myelodysplastic syndrome; ATG, antithymocyte globulin; CSA, cyclosporine A; NR, no response; MMF, mycophenolate; PR, partial response; GF, graft failure; MUD, matched
unrelated donor; hPNH, hemolytic paroxysmal nocturnal hemoglobinuria; PTLD, post-transplant lymphoproliferative disease; VSAA, very severe aplastic anemia; RCMD, refractory cytopenia with multilineage dysplasia; CR,
complete response.
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Table 2
Results of Chimerism
Days Post-Transplant No. Patients Chimerism
Tested (Total Assessable)
UF (Range) CD3 (Range) CD15 (Range)
28 6 (8) 100 (99-100) 100 (100-100) 100 (98-100)
56 6 (7) 99 (98-100) 100 (99-100) 99 (98-100)
100 6 (6) 100 (99-100) 100 (99-100) 100 (99-100)
180 5 (6) 100 (96-100) 99 (96-99) 100 (96-100)
365 4 (4) 100 (99-100) 100 (99-100) 100 (100-100)
UF indicates unfractionated.
Values in the last 3 columns are median percentages.
J. Clay et al. / Biol Blood Marrow Transplant 20 (2014) 1711e17161714haploHSCT group were small, and more patients need to be
evaluated.
For both haplo and cord blood HSCT, the presence of
recipient HLA antibodies directed against the donor is asso-
ciated with a high risk of graft rejection [15,16]. Most studiesFigure 1. (A) Patient 6. Changes in HLA antibody levels as measured by the mean ﬂuo
the bottom. Before HSCT, this patient had multiple class I HLA antibodies, of which only
the antibody level fell from a peak of 7946 MFI to 1304 immediately pre-HSCT. PEX
measured by MFI. Recipient and donor HLA typing are shown in table at the bottom.
donor directed: HLA-B45, -DR7, -DQ2, and -DR53. (HLA-DR53 is directed against a pro
After plasma exchanges and before HSCT, there was a further rise in the HLA-DR53 antof haploHSCT for SAA do not report routine assessment of
donor-directed HLA antibodies. High levels of donor-directed
anti-HLA alloantibodies most likely explain the nonengraft-
ment in 2 patients. Intensive desensitization with plasma
exchanges and rituximab was insufﬁcient to deplete therescence index (MFI). Recipient and donor HLA typing are shown in the table at
HLA-B51 was donor directed. After intensive plasma exchanges and rituximab,
indicates plasma exchange. (B) Patient 8. Changes in HLA antibody levels as
Pretransplant, this patient had class I and II HLA antibodies, all of which were
tein encoded by the DRB4 gene, which is in a haplotype with the DRB1*07:01.)
ibody, likely due to granulocyte transfusions given for invasive fungal infection.
J. Clay et al. / Biol Blood Marrow Transplant 20 (2014) 1711e1716 1715antibodies sufﬁciently to prevent graft rejection. Despite
universal leucodepletion of blood products, HLA alloimmu-
nization remains a problem in up to 30% of patients with
aplastic anemia [25,26]. In the setting of HLAmatched sibling
HSCT, this is due to minor histocompatibility antigens on
leucocytes and red cell, and in mismatched HSCT, due to HLA
antigens on leucocytes and platelets [27]. An HLA antibody
level of 1500 mean ﬂuorescence intensity is associated with
graft rejection in the setting of T celledepleted haploHSCT
and >2500 in the setting of T celledepleted matched UD
HSCT due to anti-DPB1 HLA antibodies [28,29]. In our series,
for HLA-B51 and HLA-DR53, graft rejection occurred at levels
of 1304 and 7621, respectively. Other factors contributing to
graft rejection in patient 8 were older donor age (mother’s
age of 68 years) [30], a low stem cell dose (1.8  106
CD34 cells/kg), and a female multiparous donor [28]. It may
be that transplanting a much higher CD34 dose would aid
engraftment in such cases, but this would potentially in-
crease the risk of acute and chronic GVHD. Thus, for future
cases, we agree that routine screening for HLA antibodies is
essential pretransplant and, if present, as has been recom-
mended for patients with hematological malignancies, an
alternative donor lacking HLA antigen(s) against which
recipient HLA antibody (ies) are directed should be used [16].
PBSCs have also recently been used for reduced-intensity
haploHSCT with postgraft CY in the setting of hematologi-
cal malignancy with no adverse impact on GVHD or survival
compared with BM [20,31].
In our study of SAA we showed that haploHSCT using
postgraft high-dose CY and PBSCs results in sustained
engraftment and with minimal GVHD for those patients who
lack donor-directed HLA antibodies. However, the presence
of donor-directed HLA antibodies was associated with pri-
mary engraftment failure, despite attempts to remove the
antibodies pretransplant with rituximab and plasma ex-
change. Because SAA patients have a particularly high risk of
HLA alloimmunization, it is essential that all patients are
screened pre-HSCT before considering such an approach,
because the presence of donor-directed HLA antibodies
should preclude the use of that donor.
We propose that this approach to haploHSCT now war-
rants further exploration in a larger cohort of SAA patients.
The European Group for Blood and Marrow Transplantation
Severe Aplastic Anaemia Working Party has adopted this
protocol for a future noninterventional, observational pro-
spective study of haploHSCT throughout Europe.
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